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 ABSTRACT 
 
The objectives of this study were to describe the clinico-epideiological feature of severe malaria in an area 
of markedly unstable and seasonal transmission. Also the interest was directed to characterize the immune 
response against merozoite surface proteins and variant surface antigens and to assess their impact on the 
development of different manifestation of severe malaria. The study was carried out in Gedarif area, 
Eastern Sudan during 2 successive malaria transmission seasons over the period 2000-2002.  
This is the first report about severe malaria in the Sudan and it is important for filling the paucity in the 
knowledge about the epidemiology of severe malaria.   
The incidence of severe malaria was 4.4%, and the mortality rate among the severe malaria (SM) patients 
was 6.4%, which accounts for 0.3% of all cases of malaria. Only four types of complications were 
recognized during the study period, the commonest was the severe malarial anemia (SMA) followed by 
convulsions (CAM), cerebral malaria (CM) and hypotension (HTN). Severe malaria was recognized in all 
age groups. The mean age for SM peaked at the age 2-4, while uncomplicated malaria peaked at 5-19 
years. The 4 types of severe malaria significantly differ from each other in clinically important clinico-
epidemiological indices, age, hemoglobin, blood glucose, parasite count and mortality rate. The antibody 
response directed against merozoite surface proteins (MSP119, MSP2A and MSP2B) revealed that, the 
three tested merozoite surface antigens were immunogenic. The MSP antibody response was age 
dependent in this setting. The antibody response against MSP119 was more significantly 
associated with protection from severe malaria but not uncomplicated malaria. More importantly, neither 
the prevalence nor the levels of MSP antibodies was associated with protection from fatal cerebral 
malaria.  
The study of the immune response against variant surface antigens (VSA) 
showed that the parasites obtained from patients with severe malaria, 
namely SMA and CM, displayed predominantly recognized VSA antigens 
compared to parasites obtained from patients with uncomplicated malaria 
(UM). On the other hand plasma from CM patients showed high or normal 
antibody response compared to the UM, while patients with SMA were 
found to have poor antibody response to VSA antigens expressed by 
parasites obtained from patients with different clinical grades of 
malaria. In addition it was found that, the plasma/parasite interaction 
 is influenced by the intensity of malaria transmission in the place of 
the plasma donor (Sudan or Tanzania) rather than the place of parasite 
donor. On the contrary, the VSA antibody response was more affected by 
the age of parasite donor than the age of plasma donor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   اﻟﺨﻼﺻﺔ
  
أﻳѧﻀًﺎ . أﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﺑﻐﺮض وﺻﻒ اﻷوﺟﻪ اﻟﺴﺮﻳﺮﻳﺔ اﻟﻮﺑﺎﺋﻴﺔ ﻟﻠﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة ﻓﻲ ﻣﻨﻄﻘﺔ ذات ﻃﺒﻴﻌѧﺔ إﻧﺘﻘѧﺎل ﻣﻮﺳѧﻤﻲ ﻟﻠﻤѧﺮض 
ﻟﺘﻘﻴѧﻴﻢ أﺛﺮهѧﺎ ﻓѧﻲ ﺗﻄѧﻮر ﻣﺨﺘﻠѧﻒ أﻧﺘﺠﻴﻨѧﺎت اﻟѧﺴﻄﺢ اﻟﻤﺘﺒﺎﻳﻨѧﺔ ﻨﺎﻋﻴѧﺔ ﺿѧﺪ ﻣﻴﺮوزوﻳѧﺖ اﻟﺒﺮوﺗﻴﻨѧﺎت اﻟѧﺴﻄﺤﻴﺔ؛ و ﻟﻤﺗﻤﺖ دراﺳﺔ اﻻﺳﺘﺠﺎﺑﺔ ا 
  . ﻣﻈﺎهﺮ اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة
  . 2002-0002ﺗﻢ إﺟﺮاء اﻟﺪراﺳﺔ ﻓﻲ ﻣﻨﻄﻘﺔ اﻟﻘﻀﺎرف ﺑﺸﺮق اﻟﺴﻮدان ﺧﻼل ﻣﻮﺳﻤﻴﻦ ﻣﺘﺘﺎﺑﻌﻴﻦ ﻻﻧﺘﻘﺎل اﻟﻤﺮض ﻓﻲ اﻟﻔﺘﺮة 
راﺳﺔ ﻣﻬﻤﺔ ﻟﻤﻞء اﻟﻔﺮاغ اﻟﻨﺎﺗﺞ ﻋﻦ ﺷﺢ اﻟﻤﻌﻠﻮﻣѧﺎت ﺗﻌﺘﺒﺮ هﺬﻩ اﻟﺪراﺳﺔ اﻷوﻟﻰ ﻣﻦ ﻧﻮﻋﻬﺎ ﻋﻦ وﺿﻊ اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة ﺑﺎﻟﺴﻮدان، هﺬﻩ اﻟﺪ 
  . اﻟﻤﺘﻌﻠﻘﺔ ﺑﻮﺑﺎﺋﻴﺔ اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة ﺑﺎﻟﺴﻮدان
، هѧﺬﻩ اﻟﻨѧﺴﺒﺔ %64.وﻧѧﺴﺒﺔ اﻟﻮﻓﻴѧﺎت اﻟﻨﺎﺗﺠѧﺔ ﻋﻨﻬѧﺎ ﺗѧﺼﻞ إﻟѧﻲ % 4.4أﺷﺎرت اﻟﺪراﺳﺔ إﻟﻲ إن ﻧﺴﺒﺔ ﺣﺪوث اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة ﺗѧﺼﻞ إﻟѧﻲ 
  . ﻣﻦ آﻞ ﺣﺎﻻت اﻟﻤﻼرﻳﺎ% 3.0ﺗﻤﺜﻞ 
ﻣﺜﻠѧﺖ اﻟﻤﻼرﻳѧﺎ اﻟﻤﻌﻘѧﺪة اﻟﻤﺮﺗﺒﻄѧﺔ . ﺑѧﻊ أﻧѧﻮاع ﻣѧﻦ اﻟﻤѧﻀﺎﻋﻔﺎت اﻟﻤﺘﻌﻠﻘѧﺔ ﺑﺎﻟﻤﻼرﻳѧﺎ اﻟﻤﻌﻘѧﺪة ﻓѧﻲ ﻣﻨﻄﻘѧﺔ اﻟﺪراﺳѧﺔ ﺗﻢ اﻟﺘﺤﻘѧﻖ ﻣѧﻦ وﺟѧﻮد أر 
ﺑﺎﻷﻧﻴﻤﻴﺎ أآﺜﺮ اﻷﻧﻮاع ﺷﻴﻮﻋًﺎ، ﺗﻠﺘﻬﺎ اﻟﻤﻼرﻳﺎ اﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻟﺘѧﺸﻨﺠﺎت ﺛѧﻢ اﻟﻤﻼرﻳѧﺎ اﻟﺪﻣﺎﻏﻴѧﺔ وأﺧﻴѧﺮًا اﻟﻤﻼرﻳѧﺎ اﻟﻤﻌﻘѧﺪة اﻟﻤﺮﺗﺒﻄѧﺔ ﺑﺎﻧﺨﻔѧﺎض 
أﻋﻠѧﻰ ﻣﻌѧﺪﻻﺗﻬﺎ ﻓѧﻲ ﺗѧﺼﻞ رﻳѧﺎ اﻟﻤﻌﻘѧﺪة ﻓѧﻲ آѧﻞ اﻟﻤﺠﻤﻮﻋѧﺎت اﻟﻌﻤﺮﻳѧﺔ؛ وﺟѧﺪ أن اﻟﻤﻼرﻳѧﺎ اﻟﻤﻌﻘѧﺪة ﺗѧﻢ اآﺘѧﺸﺎف وﺟѧﻮد اﻟﻤﻼ. ﺿѧﻐﻂ اﻟѧﺪم
  .  ﺳﻨﺔ51-9 ﺳﻨﻮات، ﺑﻴﻨﻤﺎ آﺎﻧﺖ اﻟﻤﻼرﻳﺎ ﻏﻴﺮ اﻟﻤﻌﻘﺪة أآﺜﺮ ﺷﻴﻮﻋًﺎ ﻓﻲ اﻟﻤﺠﻤﻮﻋﺔ اﻟﻌﻤﺮﻳﺔ 4-2اﻟﻤﺠﻤﻮﻋﺔ اﻟﻌﻤﺮﻳﺔ 
 إﺧﺘﻼﻓًﺎ ﻣﻌﻨﻮﻳًﺎ ﻓﻲ ﻋﺪد ﻣﻦ اﻷوﺟﻪ اﻟﻮﺑﺎﺋﻴѧﺔ واﻟѧﺴﺮﻳﺮﻳﺔ أﺷﺎرت اﻟﻨﺘﺎﺋﺞ إﻟﻲ أن اﻷﻧﻮاع اﻷرﺑﻌﺔ ﻣﻦ اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة ﺗﺨﺘﻠﻒ ﻋﻦ ﺑﻌﻀﻬﺎ 
أﺷﺎرت ﻧﺘѧﺎﺋﺞ اﻻﺳѧﺘﺠﺎﺑﺔ اﻟﻤﻨﺎﻋﻴѧﺔ .  و ﻣﻌﺪل اﻟﻮﻓﻴﺎت آﺜﺎﻓﺔ اﻟﻄﻔﻴﻞ  ﻣﺜﻞ ﻋﻤﺮ اﻟﻤﺮﻳﺾ، ﻣﺴﺘﻮي اﻟﻬﻴﻤﻮﻏﻠﻮﺑﻴﻦ، ﻣﺴﺘﻮي اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم، 
ﻓѧﻲ هѧﺬا . ﺔ ﺿѧﺪ اﻟﻤѧﺮض ﻳﻤﻜﻦ إﺳﺘﺨﺪاﻣﻬﺎ ﻟﺘﻮﻟﻴﺪ ﻣﻨﺎﻋѧ ( B2PSM & A2PSM ,911PSM)إﻟﻲ أن ﻣﻴﺮوزوﻳﺖ اﻟﺒﺮوﺗﻴﻨﺎت اﻟﺴﻄﺤﻴﺔ 
ﻳﺮﺗﺒﻂ ارﺗﺒﺎﻃًﺎ ﻣﻌﻨﻮﻳًﺎ ﻣﻊ اﻟﺤﻤﺎﻳﺔ ﻣﻦ اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة وﻟﻜﻦ ﻟﻴﺲ ﻣﻊ اﻟﻤﻼرﻳﺎ ﻏﻴѧﺮ ( 911PSM)اﻹﻃﺎر وﺟﺪ أن ﻣﻴﺮوزوﻳﺖ اﻟﺒﺮوﺗﻴﻦ 
ﺎ أﺷﺎرت اﻟﻨﺘﺎﺋﺞ أﻳﻀًﺎ ﻟﻌﺪم وﺟﻮد ﻋﻼﻗﺔ ﺑﻴﻦ ﻣﺴﺘﻮى اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻤﺮﻳﺰوﻳﺖ اﻟﺒﺮوﺗﻴﻨﺎت اﻟﺴﻄﺤﻲ واﻟﺤﻤﺎﻳѧﺔ ﻣѧﻦ اﻟﻤﻼرﻳѧ . اﻟﻤﻌﻘﺪة
  . اﻟﺪﻣﺎﻏﻴﺔ اﻟﻘﺎﺗﻠﺔ
أﺷﺎرت دراﺳﺔ اﻻﺳﺘﺠﺎﺑﺔ اﻟﻤﻨﺎﻋﻴﺔ ﻟﺒﺮوﺗﻴﻨﺎت اﻟﺴﻄﺢ اﻟﻤﺘﺒﺎﻳﻨﺔ إﻟﻲ أن اﻟﻄﻔﻴﻠﻴﺎت اﻟﺘﻲ ﺗﻢ ﺟﻤﻌﻬﺎ ﻣﻦ ﻣﺮﺿﻰ ﻣﺼﺎﺑﻴﻦ ﺑﺎﻟﻤﻼرﻳѧﺎ اﻟﻤﻌﻘѧﺪة 
ﻓѧﻲ . آﺸﻔﺖ ﻋﻦ وﺟﻮد اﻧﺘﺠﻴﻨﺎت ﺳѧﻄﺢ ﻣﺘﺒﺎﻳﻨѧﺔ ﺑѧﺼﻮرة ﺳѧﺎﺋﺪة ﻣﻘﺎرﻧѧﺔ ﺑﺎﻟﻄﻔﻴﻠﻴѧﺎت اﻟﺘѧﻲ ﺗѧﻢ ﺟﻤﻌﻬѧﺎ ﻣѧﻦ ﻣﺮﺿѧﻰ اﻟﻤﻼرﻳѧﺎ ﻏﻴѧﺮ اﻟﻤﻌﻘѧﺪة 
 آﺎﻧѧﺖ ﺑﻤﻌѧﺪﻻت ﻋﺎﻟﻴѧﺔ ﻣﻘﺎرﻧѧﺔ ﺑﻤﺮﺿѧﻰ ﺎ اﻟﺪﻣﺎﻏﻴѧﻪﻰ ﺁﺧѧﺮ وﺟѧﺪ أن ﻣѧﺴﺘﻮى اﻷﺟѧﺴﺎم اﻟﻤѧﻀﺎدة ﻓѧﻲ ﻣѧﺼﻞ دم اﻟﻤѧﺮﻳﺾ ﺑﺎﻟﻤﻼرﻳѧ ﻣﻨﺤѧ
  . اﻟﻤﻼرﻳﺎ ﻏﻴﺮ اﻟﻤﻌﻘﺪة ﺑﻴﻨﻤﺎ آﺎن ﻣﺴﺘﻮي اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻣﻨﺨﻔﻀًﺎ ﻟﺪى ﻣﺮﺿﻲ اﻟﻤﻼرﻳﺎ اﻟﻤﻌﻘﺪة اﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻷﻧﻴﻤﻴﺎ
اﻟѧﺴﻮدان، )اﻟﻤﻼرﻳﺎ ﺗﺘﺄﺛﺮ ﺑﻜﺜﺎﻓﺔ اﻧﺘﻘﺎل اﻟﻤﺮض ﺑﺎﻟﻤﻨﻄﻘﺔ اﻟﺘﻲ أﺧﺬ ﻣﻨﻬﺎ ﻣﺼﻞ اﻟﺪم ﺑﺎﻹﺿﺎﻓﺔ إﻟﻲ ذﻟﻚ وﺟﺪ أن ﻋﻼﻗﺔ ﻣﺼﻞ اﻟﺪم ﺑﻄﻔﻴﻞ 
  . ، ﻋﻠﻰ اﻟﻨﻘﻴﺾ ﺗﺘﺄﺛﺮ اﻻﺳﺘﺠﺎﺑﺔ اﻟﻤﻨﺎﻋﻴﺔ ﻻﻧﺘﺠﻴﻨﺎت اﻟﺴﻄﺢ اﻟﻤﺘﺒﺎﻳﻨﺔ ﺑﻌﻤﺮ اﻟﺸﺨﺺ اﻟﺤﺎﻣﻞ ﻟﻠﻄﻔﻴﻞ(ﺗﻨﺰاﻧﻴﺎ
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INTRODUCTION 
1.1. Malaria  
Malaria is one of the most wide spread transmissible diseases in the world, the name of malaria originated 
when an Italian Lancisi, in 1917 linked malaria with poisonous vapours of swamps (mal aria-bad spoilt 
air). The disease has been known to the humanity from the dawn of civilization. In the ancient Chinese 
and Egyptian manuscripts and the literary sources of ancient Greece and Rome, epidemic fever, 
symptomatically similar to malaria was described. Regarding the history of scientific discoveries in 
malariology, in 1847, the German scientist Meckel detected brownish pigment in the leukocytes-
macrophage of malarious patients; the presence of this was associated with malaria. In 1890 Marchiafa 
and Celli described Plasmodium falciparum. In 1897 Ronald Ross proved experimentally that mosquitoes 
serve as vectors of human and avian malaria (1).  
Malaria is considered as one of the main health problems in Sudan and the disease was known to affect 
adults as well as children (2), and causes death for 1.5% of the in-patient individuals (3).  Plasmodium 
falciparum was found to be the causative agent for 98% of malaria infections in Eastern Sudan, with 
Plasmodium vivax and Plasmodium malariae occasionally seen (4). 
Globally, 300–500 million clinical cases are detected annually with an estimated mortality of 1.5–2.7 
millions. Approximately one million deaths among children less than five years of age are attributed to 
malaria alone or in combination with other diseases. Countries in tropical Africa are estimated to account 
for more than 90% of the total malaria incidence and the great majority of malaria deaths (5). 
 
1.2. Severe malaria 
Malaria causes 3000 deaths per day, with annual total that exceeds one million deaths worldwide (6). 
Severe and complicated malaria is a fatal form of human Plasmodium falciparum malaria that associated 
with the failure of the host defenses to control parasite replication, excessive secretion of pro-
inflammatory cytokines and sequestration of parasitized erythrocytes in vital organs (7). In clinical 
practice severe malaria can be manifested in different forms starting with the severe cerebral malaria, 
prostration, impaired consciousness, severe malaria anemia, hypoglycemia, repeated multiple convulsions, 
circulatory collapse, respiratory distress, hyperlactataemia, abnormal bleeding, jaundice, haemoglobinuria, 
renal impairment, and pulmonary edema (radiological)(8).  
1.2.1. Pathogenesis of severe malaria 
 The epidemiological profile and clinical pattern of severe malaria in Africa, has been shown to be 
modulated by the intensity of exposure and pattern of transmission (9). Severe complications in areas 
highly endemic for Plasmodium falciparum malaria such as tropical Africa predominantly affects children 
in the age group of 1-5 years i.e. children that have not yet developed a sufficient anti-disease immunity. 
Cerebral malaria is not so common in regions with perennial or hyper-holoendemic transmission where 
Plasmodium falciparum is transmitted all around the year.  The severe forms of the disease are in other 
areas frequently seen both in children as well as in adults reflecting a less intense transmission pattern of 
Plasmodium falciparum infections (10).  
A number of substances have been proposed to be responsible for severe disease. The cytokines, reactive 
oxygen species (ROS), and nitric oxide (NO) have been implicated with the possibility of a dual role for 
some, in which these substances are involved in both the pathogenesis of severe disease and killing the 
parasite (11). Cytoadherence is believed to be a key factor in the development of severe malaria. Although 
the property of cytoadherence is universal, under some conditions parasites appear to accumulate in 
particular organs in large numbers and cause damage by mechanisms that are poorly understood. These 
may include impairment of the local circulation or the induction of the release of local mediators such as 
cytokines or nitric oxide (12). 
1.2.1.1. Cytokines 
Macrophages of the spleen red pulp are apparently assumed to be involved in eradicating infected 
erythrocyte under normal circumstances. Gamma delta T cells (γ/δ-T cells) also have been shown to be 
involved in controlling the parasitism. These findings fit with data ascribing early production of interferon 
gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) both to splenic γδ T lymphocytes and to natural 
killer (NK) cells that activated by macrophages IL-12 (13). In addition it was proposed that malaria 
parasite directly induce TNF-α from macrophages and this initiate the characteristic pyrogenic response to 
malaria infection and up-regulate expression of endothelial adhesion molecules in the brain allowing 
sequestration of Plasmodium falciparum infected erythrocytes and interference with cerebral perfusion, 
leading to comma. Plasmodium vivax does not lead to cerebral malaria despite very high plasma 
concentration of TNF-α (14).  
Animal models of malaria have provided convincing evidence of the important role of inflammatory 
processes in the development of cerebral malaria. Although none of them completely duplicates the 
situation in humans. Not all pro-inflammatory cytokines are equally relevant for the development of 
cerebral malaria. The best documented evidence implicates IFN-γ, TNF-α and IL-12. The elevations in 
 TNF may exacerbate the tendency to sequestration by the up regulation of host ligand molecules 
responsible for cytoadherence of parasites, increasing mechanical obstruction of cerebral or other blood 
vessels (11).  
Most of the evidence supporting an immunological involvement in malarial anemia comes from data 
related to the role of IL-12, a cytokine that boosts erythropoiesis. The levels of IL-12 were found to be 
correlated with anemia in this pathology (15), and the administration of recombinant IL-12 was able to 
ameliorate anemia in A/J mice infected with Plasmodium chabaudi (16). The implications of high levels 
of immune regulatory cytokine IL-10 in Plasmodium falciparum malaria are unclear. IL-10 may down-
regulate pro-inflammatory responses and also exacerbate disease by inhibiting anti-parasitic immune 
functions (17).  Contradicting results were reported concerning the levels of TNF-α in serum of severe 
anemia patient (18,19). 
A high TNF early in malarial infection and during the acute phase of malaria predicted protective role and 
rapid clinical and parasitological cure, whereas prolonged, high TNF levels may be determinal. These 
finding illustrate the dual role of cytokines in the protection and pathology of malaria (20,11) and indicate 
the importance of timing and amounts of different cytokines that released, particularly TNF, that might be 
an important determinants of subsequent patho-physiological events and perhaps mortality. The ratio of 
anti-inflammatory cytokines over pro-inflammatory cytokines in serum has been proposed to be the 
accurate determinant of the severity of anemia (21,22).  
1.2.1.2. Reactive oxygen species (ROS)  
Clark and others (23) proposed that ROS might play a role in the pathogenesis of severe malaria. They 
subsequently suggested that extravasated erythrocytes might lead to ROS generation, causing comma and 
damage to local tissues, including the brain. ROS produced by leucocytes may also kill the parasites. In 
humans there is some evidence that ROS play a role in pathogenesis (11). Griffiths and his colleagues (24) 
demonstrated that malaria infection might be associated with oxidative damage and reduced alpha-
tocopherol reserve in erythrocyte membrane, suggesting that local antioxidant depletion may contribute to 
erythrocyte loss in severe malaria. They also demonstrated that erythrocyte membrane alpha-tocopherol 
appeared a better indicator of ROS exposure than plasma.  
1.2.1.3. Nitric oxide (NO) 
NO is constitutively produced in certain tissues, and in response to inflammatory stimuli through the 
action of cytokines which up-regulate the synthesis of inducible NO synthase (iNOS2 or NOS2) (11). NO 
was suggested to be produced from peripheral blood mononuclear cells (PBMCs) and other tissues and 
 cellular sources in response to Plasmodium falciparum malaria (25). NO has been proposed as a mediator 
of malarial tolerance, where asymptomatic children have higher level of NO than children with severe 
disease. The above tolerance may be mediated by one or more of the followings; inhibition of parasite 
growth (26), intracellular parasite killing by reactive nitrogen metabolites (27) or having anti-adhesive 
effect (28). Interestingly, NO seems not to be involved in the pathogenesis of cerebral malaria (13), and 
the implication of NO in severe malaria may be due to a genetic polymorphism in the NOS2 gene or 
different haplotypes (29,30). Data suggested a role of inducible nitric oxide synthase (iNOS) variants, 
which affect the ability of macrophages to release reactive nitrogen metabolites in response to TNF-α and 
IFN-γ, which influence the progression to cerebral malaria and to severe infection (31). 
1.2.1.4. Cytoadherence, rosetting and sequestration  
Rosetting is the adhesion of Plasmodium falciparum infected erythrocyte to uninfected erythrocytes, 
which is suggested to be mediated by PfEMP1 as the ligand and heparin sulfate or a heparin sulfate-like 
molecule as a receptor. Rosetting is regarded as a virulent parasite phenotype associated with the 
occurrence of severe malaria (32). 
Sequestration is the adherence of infected erythrocytes containing late developmental stages of the 
parasites (mediated by PfEMP1) to the endothelium of capillaries and venules and is a characteristic of 
Plasmodium falciparum infections (33) and contributes directly to acute malaria pathology (34). 
Sequestration favors the development of the parasite by protecting it from the filtering action of the 
spleen; it is also responsible for the severe clinical forms of cerebral malaria in which brain capillaries are 
obstructed by sequestered parasites (33)(reviwed by David et al. 1983).  
 The mechanisms of parasite sequestration remain unclear. Ultrastructural studies have suggested that 
adherence of parasitized erythrocytes to the vascular endothelium occurs by means of the knobs on the 
infected erythrocyte membrane (33). These knobs are seen at the point of contact between the infected red 
blood cells (iRBCs) and endothelial cells, the knobs are made up of parasite-encoded proteins that have 
been exported to the surface of the infected erythrocyte. They are essential for firm cytoadherence by 
facilitating the initial attachment and by concentrating the parasite ligands at a particular site. Although 
knobless iRBC can adhere in static binding assays in vitro, ultrastructural studies of human tissues from 
fatal malaria cases have not shown cytoadherence independent of knobs (35). Gilks and his coworker (36) 
stated that there were several lines of evidence showed that variant surface antigen expression and the 
sequestering phenotype are closely linked and co-expressed, or functions of the same antigen.  
Individual variant surface antigens (VSA) can bind to different combinations of microvasculature 
 endothelial receptors, including thrombospondin, CD36, intercellular adhesion molecules 1 (ICAM-1), 
vascular cell adhesion molecule, E-selectin, CD31, P-selectin, chondroitin sulfate A, and αvβ3 integrin 
(37).  
Until recently, Variant surface antigens (VSA) were thought to be made up exclusively of Plasmodium 
falciparum erythrocyte surface protein-1, but recently rifins were described which are clonally variant 
surface proteins expressed on the surface of red cells infected with Plasmodium falciparum; but their role 
in the agglutination of field isolates is still unknown (37).  
PfEMP1 has been reported as a parasitized erythrocyte receptor for adherence to CD36, thrombospondin 
(TSP) and intercellular adhesion molecule-1 (ICAM-1) (34). It is important to note that whereas virtually 
all isolates show the phenotype of adherence to CD36 and TSP, adherence to the other receptors is an 
isolate- and variant-specific property (12). Isolates that bind to multiple receptors were found to be 
involved in the causation of severe malaria and that several receptor-ligand interactions work 
synergistically in bringing about severe disease (38). 
Naturally induced antibodies binding to surface antigens of Plasmodium falciparum – infected 
erythrocytes can be detected by direct agglutination or by indirect immunoflourescence, the results 
obtained by both methods generally correlate well. The agglutinating antibodies predominantly recognize 
variant-specific epitopes of PfEMP1 that is the adhesin mediating adhesion of Plasmodium falciparum -
infected erythrocytes to the endothelial wall (39). Using flow cytometry, Staalsoe and others (39) 
demonstrated that the adhesive capacity of a parasite isolate correlates with the capacity of human 
immune plasma to label the isolate and the antigen recognized are strain specific and their molecular 
weights are in the range previously described for PfEMP1 antigens.  
Immune serum can inhibit and reverse in vitro binding of infected erythrocytes from intact animals to 
melanoma cells. Similarly, antibody can reverse in vivo sequestrations as shown by the appearance of 
trophozoite/schizont-infected erythrocytes in the peripheral blood of an intact animal after inoculation 
with immune serum. So the spleen was regarded as the organ that modulates the expression of parasite 
alterations of the infected erythrocyte membrane responsible for sequestration and suggests that the 
prevention and reversal of sequestration could be one of effectors mechanisms involved in antibody-
mediated protection against Plasmodium falciparum malaria (33). 
Antibodies directed to the variant antigens on the surface of infected erythrocytes were found to be 
associated with protection from malaria (40,41). 
In areas of high intense Plasmodium falciparum malaria transmission, malaria among pregnant women is 
 both more prevalent and more severe than in non-pregnant women (42,43). Pregnancy associated malaria 
(PAM) is characterized by marked accumulation of parasites in the intervillous space of the placenta, and 
is the cause of maternal anemia as well as low birth weight, prematurity and increased infant mortality 
(44,43). PAM is characterized by the placental accumulation of infected erythrocytes that adhere to CSA 
and that the susceptibility to PAM decreases with increasing parity, apparently due to acquisition of 
antibodies directed against VSACSA. There is an evidence that-specific antibodies are linked to placental 
infection and that high antibody levels contribute to the control of placental infection by inhibiting 
parasite adhesion to CSA. Data suggest that VSACSA is a target for vaccination against PAM (45). 
 
1.3. Malaria parasite and life cycle (Figure 1.1)  
 Malaria is a protozoal infection caused by Plasmodium species. Over 70 species of malaria parasites that 
infect monkeys, rodents and, birds are known (1). 
The multi-stage protozoan parasites Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale and 
Plasmodium malariae are the etiological agents of malaria infection in human. Plasmodium falciparum is 
the most widely spread and the most fatal of the human malaria. Two hosts are involved in malaria life 
cycle, a vertebrate (man) and an invertebrate (female Anopheles mosquito). 
Infection is initiated by the injection of sporozoites into the blood stream during feeding of infected 
female Anopheles mosquitoes. The sporozoites migrate to the liver, where they invade hepatocytes (pre-
erythrocytic phase) and undergo a phase of maturation and asexual reproduction (schizogony) to release 
into the blood tens of thousands of free merozoites.  
The invasion of merozoites into circulating red blood cells initiates the erythrocytic phase of the life cycle. 
Invasion is a complex series of events from RBC binding, to apical orientation, junction formation and 
signaling the start of the invasion process. Invasion events include releasing essential molecules from the 
invasive apical organelles (rhoptries, micronemes and dense granules) and initiating the actin-myosin 
moving junction that bring the parasite inside the vacuole that forms in the RBC. What remains 
completely unknown is which merozoite surface molecules recognize the erythrocyte surface and then 
signal the start of the invasion process (46).  
Schizogony is repeated within the erythrocytes, and infected red cells rupture and release more merozoites 
into the circulation to begin another erythrocytic cycle. Alternatively, a proportion of invading merozoites 
differentiates into male or female gametocytes which, when ingested by a mosquito, emerge from the 
erythrocyte to form gametes. After fertilization, the zygote (ookinete) migrates across the mosquito 
 midgut wall and matures within the body cavity. The resulting 
oocyst produces sporozoites that migrate to the mosquito salivary glands where they mature and become 
infectious to humans. Only the asexual erythrocytic stage of the life cycle is associated with pathogenesis 
of the disease. 
Each phase of the life cycle is associated with the expression of a number of stage-and species- 
specific antigens, many of which are located within the surface membrane of the parasite and appear to be 
targets for naturally acquired immune responses (47).  
It has been established that the blood forms of Plasmodium falciparum species are haploid (48). The 
diploid phase is being probably restricted to the ookinete stage in mosquitoes (49). Meiosis occurs within 
a few hours (50), followed by further mitotic division to produce haploid sporozoites. Each oocyst thus 
contains the meiotic products of a single zygote. The mixture of clones of  Plasmodium falciparum 
ingested by mosquitoes undergo cross mating, meiosis of such heterozygotes leads to recombination 
between genes, with the consequent production of parasites with novel genotypes (51). 
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1.4. Epidemiology of malaria 
Malaria continues to be a threat to hundreds of million of people living in endemic areas and to travelers 
visiting these regions (52). Its transmission however is possible only when a combination of several 
factors is available, including sources of infection, vectors, susceptible population and favorable natural 
and climatic conditions. The source of infection is a malaria patient or asymptomatic parasite carriers in 
endemic areas. Intrauterine infection, blood transfusion and the use of non-sterile syringes among drug 
addicts represent another route of transmission. Under natural conditions, female mosquitoes of the genus 
Anopheles usually serve as a vector or host for the sexual cycle of parasite development. Transmission of 
malaria parasites occurs in the appropriate climatic conditions such as temperature higher than 16oC. and 
 the presence of either stagnant or slowly flowing water. The transmission intensity depending on the 
number of mosquitoes and the type of species they belong to (1).  
The disease is “endemic” where there is a constant measurable incidence of cases and natural transmission 
over a succession of years. It is “epidemic” where the incidence of cases in an area rises rapidly and 
notably above the usual levels, or where the disease suddenly occurs in an area previously non-malarious. 
An epidemic becomes “pandemic” when it spread far beyond usual limits. The prevailing frequency and 
intensity of malaria are referred to as “malaria endemicity”. Two systems are used to estimate the level of 
endemicity, the first deals with the parasite rate among children aged 2-9 years (53). The second deal with 
the spleen rate among the same age group (54). Malaria is “holoendemic”: where the parasite or the spleen 
rate is constant over 75% and the adult's populations have high tolerance. Malaria is “hyperendemic” 
where the parasite or the spleen rate is constantly over 50 % and also the rate is high in adults. 
“Mesoendemic” where the parasite or the spleen rate is ranged 11-50 %. “Hypoendemic” where, parasite 
or the spleen rate is 10 % or less. Transmission is “stable” when the prevalence is relatively steady from 
year to year and season to season, and if there is a wide difference, it is called “unstable”. 
Endemic and epidemic malaria results from a complex interplay of numerous factors, the most important 
being, of course, man as a carrier of gametocytes, the Anopheles mosquito as vector, and man as recipient 
of infection. The following factors modify this chain of transmission from man to mosquito to man: the 
species and strain of Plasmodium; the immune status of host (man); bionomics or habits of man and 
mosquito; environmental conditions, such as temperature, relative humidity, rainfall, topography, soil, 
flora, and fauna, control measures applied to mosquitoes, and treatment of man by therapeutic and 
prophylactic drugs (55). Epidemiological studies have shown that the development of resistance to 
malaria in man depends on both the degree and the duration of exposure to malaria parasite. A primary 
malaria infection is not followed by the development of solid immunity and most of the deaths occur in 
young children in endemic areas and in infected adults with no previous history of exposure to the malaria 
parasites. Immunity builds up in the course of successive infection and sterile immunity is probably never 
achieved. In endemic areas, clinically significant malaria becomes infrequent in adults with the exception 
of pregnant women. However, transient parasitaemia is still observed (56). Protection to malaria acquired 
by individuals living in endemic areas is largely governed by the transmission pattern (57), and the 
development of disease immunity is characterized by a decrease in the frequency and severity of disease 
episodes over several years despite almost continuous infection (58). 
The apparently slow acquisition of protective immunity in children to Plasmodium falciparum malaria 
 may have several reasons, including effects of the parasite on immune regulation resulting in suppression 
of specific immune responses (59). Other factors include the genetic diversity or variability of the human 
host or parasite antigens giving rise to potentially protective immune responses.  
 
1.5. Malaria control  
Malaria parasites have defied all attempts to eradicate, the reasons for this failure are complex, briefly 
might be due to the complexity of the parasite life cycle that involves more than one host, and the 
development of antigenic diversity, in addition to the wide spread of drug resistant parasites and vectors. 
The low educational and socio-economical statuses of the inhabitants of malaria endemic areas also play 
roles in this failure. These status lead to the failure of the control programs concerning the control of the 
mosquitoes breeding sites and limit the use of the insecticide impregnated bed nets that have been 
succeeded in controlling malaria vectors in different endemic areas (60,61). WHO realized that the global 
eradication of malaria was impossible and the focus shifted to control.   
1.6. The malaria parasite genome 
The Plasmodium falciparum 3D7 clone sequence was launched in 1996 and completed in 2002 reported a 
unique sequence of this eukaryotic organism. Analysis of the genome sequence provides a global view of 
the metabolic potential of Plasmodium falciparum irrespective of the life cycle stage.  The 22.8 mega-base 
nuclear genome consists of 14 chromosomes ranging in size from approximately 0.643 to 3.29 Mb and 
encodes about 5,300 genes, and it has been regarded as the most (A + T) rich genome sequenced to date. 
The overall (A + T) composition is 80.6 % and rises to ~90 % in introns and intergenic regions. Excluding 
introns, the mean length of Plasmodium falciparum genes was 2.3 kb, substantially larger than in the other 
organisms in which the average gene lengths range from 1.3 to 1.6 kb. Genes involved in antigenic 
variation are concentrated in the sub-telomeric regions of the chromosomes, so the understanding of sub-
telomere structure and functional properties is essential for the elucidation of the mechanisms underlying 
the generation of antigenic diversity. Compared to the genomes of free-living eukaryotic microbes, the 
genome of this intracellular parasite encodes fewer enzymes and transporters, but a large proportion of 
genes are devoted to host-parasite interactions and immune evasion. At least 1.3 % of Plasmodium 
falciparum genes are involved in cell to cell adhesion or the invasion of host cells and 3.9 % (208 genes) 
known to be involved in the evasion of the host immune system (62).  
The malaria genome sequencing consortium estimated that more than 60% of the 5,409 predicted open 
reading frames (ORFs) lack sequence similarity to genes from any other known organism (62). The 
 function of these elements is still not clear. One might speculate that the ORF- sequences are transcribed 
as poly-cistronic mRNA’s together with a specific var gene and encode proteins necessary for functional 
var gene expression on the cell surface. Alternatively, it is tempting to speculate that some of the ORF- 
elements are spliced to the large exon I of a var mRNA giving new biological properties to the var protein 
(63). 
The chromosome mapping data demonstrate several features common to all Plasmodium falciparum 
chromosomes: house keeping genes map to the central chromosome regions whereas the genes encoding 
immunodominant antigens are generally located at the polymorphic chromosomes extremities. The 
compartmentalization of Plasmodium falciparum antigen genes to the highly recombinogenic 
chromosome ends can lead to related variant antigen gene families scattered on several chromosome 
extremities. The constant turn over of Plasmodium falciparum DNA at chromosome ends also implies that 
new gene linkage groups are continually being formed. Over the long term this constant turn over is a 
powerful adaptive mechanism by which Plasmodium falciparum parasites create functional diversity. 
Plasmodium has in addition to the nuclear genome, two unrelated organellar genomes. One is 
mitochondrial and the other probably of plastid origin of 35 kb (63). The mitochondrial genome of 
Plasmodium falciparum is small about 6 kb and encodes no tRNAs (62).   
Genetic diversity can be generated during the sexual or asexual stage of the parasites’ life cycle by several 
mechanisms. During mitosis these include mutation, chromosome breakage, unequal sister chromatid 
exchange, gene conversion or inter-chromosomal exchange. During meiosis, reassortment of 
chromosomes, recombination between homologous or heterologous chromosomes, unequal sister 
chromatid exchange or gene conversion can also occur (64).  
 
1.7. Plasmodium  falciparum Antigenic diversity 
Mc Bride et al. (1982) has reported antigenic diversity in the human malaria parasite Plasmodium 
falciparum, stage and strain specific but no clear regional differences were seen, since identical antigenic 
combinations occurring in isolates from different parts of the world. There are two aspects of antigenic 
diversity among malaria parasites that need to be distinguished (65).  
1.7.1. Antigenic polymorphism  
Polymorphisms in allelic genes give rise to the expression of structurally and antigenically distinct forms 
of a particular protein in different parasites and this can be demonstrated by the variations in the merozoite 
surface proteins 1 and 2 (MSP1 and MSP2). Because there are large numbers of different polymorphic 
 genes that are not linked, and there is recombination and re-assortment of these genes during meiosis, 
there is the potential for a very large numbers of different genotypes within one species of Plasmodium 
(66). A sexual blood stage of Plasmodium falciparum can be conveniently classified into those exhibiting 
minor polymorphism involving point mutation and those in which there are major polymorphism often 
involving change in repetitive sequences (67). 
 
1.7.2. Antigenic variation  
Antigenic variation is a phenomenon by which a clonal population of parasite can changes its antigenic 
phenotype. Plasmodium falciparum contains four families of highly variable gene termed var, rif, stevor 
and Pf60, which code for proteins known as Plasmodium falciparum erythrocyte membrane protein -1 
(PfEMP-1), repetitive interspersed family (rifin), sub-telomeric variable open reading frame (STEVOR) 
and 6.1 protein respectively (62,68). The sequencing of the 3D7 genome contains 59 var, 149 rif and 28 
stevor genes, but for each family there are also a number of pseudogenes and gene truncations present 
(62). These pseudogenes may code for Pf60 where the majority of the 90 copies per haploid genome code 
for Pf60 appear to be pseudogenes because they contain frameshifts or internal stop codons (12).  
The differential expression of these genes results in antigenic variation which is used as a mechanism for 
immune evasion. Babiker & Walliker (1997) in their study of the var gene as one of these multifamily 
genes assumed that if these large repertoires contain many allelic variants at each locus in the parasite 
population the number of genetically distinct clones that could be generated by recombination seems 
almost infinite (51).  
 Variant gene families have also been identified in all other malaria parasite species investigated. Some of 
these genes have been shown to be located in subtelomeric regions of the chromosomes, many are 
distinctly different in structure and sequence from those identified in Plasmodium falciparum, indicating 
that they might have evolved independently and have different functions (69). 
1.7.2.1. The var gene 
When Su et al., (1995) tried to find the drug resistant gene; they fortuitously discovered a number of 
adjacent genes that look like genes encoding members of the PfEMP1 family, they call these genes var 
genes.  Su and his coworker (70) have sequenced four genes of the var family. The deduced protein 
sequences look like cellular adhesion molecules; where, they appear to consist of a large and variable 
extra-cellular domain, a single trans-membrane segment, and a conserved intracellular domain. As 
expected for a variant antigen, the extra-cellular domains of different members of family are very different 
 in sequence, although they share an overall similarity in structure. Smith et al. (1995) put an indication 
that the var genes encode the variant surface antigen of Plasmodium falciparum and are the basis of 
antigenic variation and binding to endothelium. Also they presented the most extensive analysis that 
confirmed the differential expression of the members of the var gene family in different parasite lines. 
They didn’t find evidence for duplicate copies of expressed genes, they found a deletion in var genes but 
this deletion did not correlate with change in antigenic phenotypes. Multiple var expression sites exist, 
since transcripts from different chromosomes were identified (71). Var genes are located predominantly at 
chromosome ends (approx. 20 to 40 kb from the telomere repeats) in subtelomeric regions next to the non-
coding element rep20 as well as central chromosome regions (63). Var genes are encoded in two exons, 
the first exon includes the extracellular region and a putative trans-membrane domain. The second exon 
encodes the acidic terminal segment (ATS), a domain that is hypothesized to anchor PfEMP1 at knobs 
(72). 
A study of different clones of Plasmodium demonstrated that the differential control of var gene 
expression must be tight; implying that a single infected erythrocyte may only express one or at most a 
few var genes (73).  
Within the 3D7 genome, there are 59 intact var genes, with 149 rif and 28 stevor genes interspersed near 
the var genes (62). Whereas rif and stevor genes appear to be closely related, the var genes are unique and 
are the most extensively studied variant gene family. Plasmodium falciparum populations harbour many 
var forms, whose diversity and continual renewal support the success of the species against host 
immunity. Var gene sequences undergo recombination at frequencies much higher than those expected 
from homologous cross-over alone. These recombination events occur between sub-telomeric regions of 
heterlogous chromosomes, which associate in clusters near the nuclear periphery in asexual blood stage 
parasites or in bouquet-like configurations near one pole of the elongated nuclei in sexual parasite forms 
(74). This clustering should bring the subtelomeric genes into alignment, thus facilitating recombination 
event between genes that are positioned similarly along the chromosome (74,75).   
The recombination preferentially occurs within var gene groups (76), where close examination and 
analysis of the var gene sequences indicate that most of the family can be divided into three broadly 
defined classes based on chromosomal location (sub-telomeric or central), direction of transcription 
(towards or away from the telomeres), and type of the semi-conserved upstream flanking region (referred 
to as UpsA, B or C) (69). It is speculated that the groups reflect a functional diversification evolved to 
cope with the varying conditions of transmission and host immune response directed against the parasite 
 (76).   
The work done by Rowe and his colleagues (77) was the first to describe sequence conservation in the 
PfEMP1 family that binds to the host receptor chondroitin sulfate A (CSA) called var1 subfamily. 
Another gene belongs to a second subfamily (var2csa) was reported to be implicated in the pathogenesis 
of pregnancy associated malaria (PAM). The var2csa genes are structurally distinct from all other var 
genes in the parasite genome in lacking both CIDR and DBL-γ domains. These domains have previously 
been implicated in PfEMP1-mediated adhesion to CD36 and CSA (43). This conservation may be 
explained by the orientation of the gene where, most sub-telomeric genes transcribed toward the 
centromere but this CSA-binding gene is transcribed towards the telomere and this inverted orientation 
doesn’t favor ectopic recombination (76,77).  
The mechanisms of switching in the expression of the var genes have yet to be understood. The chromatin 
structure could play a major role in transcriptional activation of individual var genes; mechanisms that 
regulate chromatin structure such as the histone deacetylase may be key modulators in Plasmodium 
falciparum gene regulation (78). For example, the deacetylation of histones is correlated with 
transcriptional silencing (79). Thus Scherf and his coworker (63) speculate that chromatin structure could 
be reversibly modified to activate or inactivate var gene transcription by targeting histone 
acetyltransferase and deacetylases to a particular var gene. Both chromatin structure and DNA 
modification might work hand in hand in the regulation of transcription control. Deitsch and his 
colleagues suggested that further control elements in the intact var gene are required to control or silence 
expression, when they found that silent var promoters become transcriptionally active when they removed 
from their chromosomal context. They later showed that the silencing is established during the DNA 
synthesis phase (S phase) of the cell cycle and that it depends on the cooperative interaction between two 
elements in separate control regions of each var gene (the 5’ flanking region and the conserved intron 
which separate the two exons of all var genes)  (80). The var gene is found to be expressed in apparently 
large and varied numbers at the sporozoite stage as well (81).  
 
1.7.2.2. Repetitive interspersed family (rif) 
Repetitive interspersed family (rif) sequences were originally identified as multi-copy Plasmodium 
falciparum sequences but were not studied further because they appeared to be short open reading frames 
with no obvious translation start site. The genome project revealed the presence of a spliced exon about 
300 base pairs upstream of each rif that encoded a translational start and a putative signal sequence. This 
 suggested not only that rif genes encode proteins but that their high copy number (∼200 per genome) and 
high degree of polymorphism might indicate another variant antigen family. Evidence to date suggests 
that the encoded proteins (RIFINs) are expressed in trophozoites, are located on the infected red cell 
surface, and undergo antigenic variation. Currently no function has been ascribed to members of this 
family, although there is a suggestion that they might act as cofactors in rosetting or in binding to CD31 
(12). 
1.7.2.3. Subtelomeric variant open reading frame (stevor) 
The subtelomeric variant open reading frame (stevor) is localized in Maurer’s clefts, unique membranous 
structures located in the cytoplasm of infected erythrocytes. The timing of stevor expression that occurs 
over just a few hours of the asexual parasite life cycle and the location of STEVOR are clearly distinct 
from those of other parasite variant antigens suggesting that this gene family may have a novel role in 
Plasmodium falciparum biology (82).   
1.7.2.4. Pf60 
The Pf60 family shares a high degree of homology to the second exon of PfEMP-1, is composed of 
roughly 90 copies per haploid genome. From the malaria genome project, the majority of these sequences 
appear to be pseudogenes because they contain frameshifts or internal stop codon (12). However the one 
member of this family that has been fully characterized to date has a series of additional 5′ exons and is 
expressed via a translational frameshift an interesting mechanism that has only recently been described in 
Plasmodium falciparum. The Pf60.1 gene is constitutively expressed by all mature blood stages and codes 
for a protein located within the nucleus (68).  
 
1.8. Immunity to malaria 
Responses to malaria infection are regulated by both the innate and adaptive acquired immune system as 
well as by environmental factors. Acquired immunity is both species and stage specific. It is rarely sterile 
but rather associated with low grade parasitemia and episodes of clinical disease throughout life (83). In 
areas of endemic Plasmodium falciparum malaria transmission, neonates are relatively protected from 
severe malaria compared with older children. It is not clear whether resistance in neonates is primarily 
physiological (for example, erythrocytes containing fetal hemoglobin only poorly support parasites 
growth, the breast milk is relatively deficient in para-aminobenzoic acid (P-ABA), which is an essential 
nutrient for parasite growth), or immunological (mediated by maternal immunoglobulin transferred across 
the placenta, or the human breast milk which contains high concentration of transforming growth factor 
 beta (TGF-β) which is, if absorbed intact into the infants blood stream, might exert a systemic anti-
inflammatory effect (14).  
1.8.1. Innate natural immunity 
The observation that host genetic factors can modify disease outcome is an importance factor when 
considering global pattern of human migration. Morbidity and mortality due to malaria will be 
substantially greater upon exposure of individuals who are innately susceptible to this disease. Such group 
may be selectively targeted for interventions. 
Several host factors play a crucial role in the survival of the parasite by determining host resistance or 
susceptibility to infection by Plasmodia, (lack of the Duffy blood group antigens on erythrocytes confer 
resistance to P. vivax infection). Heterozygotes for haemoglobinopathies and other disorders of the red 
cell (thalassemia, sickle cell anemia and glucose-6-phosphate dehydrogenase deficiency), promote innate 
resistance to Plasmodium falciparum infection; such protection is probably triggered by modifications of 
parasite development within the erythrocytes (57). Recently, hemoglobin HbC has been reported to 
protect against severe malaria (84) may be by reducing PfEMP-1 mediated cytoadherence (85). 
Elagib and others (86) suggested that the haptoglobin phenotype (1-1) is associated with susceptibility to 
falciparum malaria and the development of severe complications.  
Polymorphic forms of number of host genes involved in immunity have been associated with protection or 
susceptibility to malaria; Polymorphic point mutations at the human tumor necrosis factor (TNF) promoter 
region have been reported to be associated with severe malaria anemia, and other variant is associated 
with cerebral malaria (87). 
FcγRIIa (CD32) on the surface of lymphocytes and monocytes/macrophages provides an important link 
between humoral and cellular immune systems. However, the recognition of IgG by CD32 is influenced 
by polymorphism within the gene. The functional activity of immunoglobulin subtypes is likely to 
depend, at least in part, on the CD32 genotype of the host and an association between FcγRIIa (CD32) 
polymorphism and increased susceptibility to severe malaria has been reported (88).  
The genetically determined low Complement receptor type 1 (CR1; CD35) density on erythrocytes may 
be a risk factor for developing a more severe form of malaria (89). 
The presence of variants of genes encoding adhesion molecules, such as ICAM-1 and CD36, may also 
affect the outcome of malarial infections; these molecules are also involved in the immunity regulation. 
ICAM-1 is expressed on activated endothelial cells, dendritic cells and lymphocytes and is preferentially 
up-regulated on memory T cells. ICAM-1 binding to infected erythrocytes exhibits parasite strain 
 specificity, and one host variant is associated with susceptibility to cerebral malaria in West Africa. CD36 
is expressed on endothelial cells, platelets, macrophages and dendritic cells. Several polymorphic forms 
have been detected, one polymorphism found to confer protection against severe anemia by reducing 
parasite sequestration. There is evidence to suggest that interaction of CD36 on dendritic cells with 
specific Plasmodium falciparum strains leads to defects in dendritic cell maturation. Therefore, 
polymorphism in CD36 may affect the priming of immune responses during infection, as well as parasite 
sequestration (31). 
1.8.2. Acquired immunity 
Acquired immunity to Plasmodium falciparum is species, stage, and strain-specific (90, 91) involving 
interactions between several different immune mechanisms (92). Adaptive ‘specific” immune responses 
are mediated by T-lymphocytes (T-cells) and B-lymphocytes (B-cells).  
Defense mechanism of immunity are mediated and regulated through a sublime interplay between 
different parts of the system and that all parts of the system cooperate with each other, specific as T and B 
cells or non specific as the white blood cells and the natural killer cells (NK). T-cell stimulates NK-cells 
and monocytes through the secretion of interferon gamma (IFN-γ). Antibodies often opsonize 
microorganisms that can easily be taken up by phagocytic cells; the T-cells in turn regulate the production 
of antibodies by B-cells (57). 
Natural killer cells have a cytotoxic activity and can recognize potential target cells that has been coated 
with antibodies through CD16 IgG Fc receptor on the NK cells which is known as antibody dependent cell 
mediated cytotoxicity (ADCC) (93).  
1.8.2.1. Arms of the acquired immunity  
1.8.2.1.1. The cell mediated immune response 
The role of T-cells in the protection against malaria was emphasized by studies in animal models in which 
intact animals developed solid natural immunity after infection whereas thymectomized animals failed to 
do so (94). T-cells might participate in the protection against malaria as helper cells for antibody 
production by regulating the activation of B-cells. As cytotoxic cells to infected hepatocytes, T-cells also 
produce IFN-γ, which is toxic to the liver stage of the parasite. Macrophage/monocytes activation is also 
regulated by T-cells. Theander (57) concluded from the animal and human studies that Plasmodium 
falciparum infections result in an immunological memory at the T-cell level. The functions of these cells 
in the development and execution of immunity is probably to regulate macrophage activation and 
antibody production. Ferreira and his coworkers (95) reported that interferon-γ released by immune T-
 cells have been shown to kill intra-hepatic parasites in vivo. Both T-cells with TCRαβ+ or TCRγδ+ have 
been shown to secrete IFN-gamma after malaria antigen activation. TCR γδ cells are primarily activated 
by live parasites and the activation depends on secretion of interleukin 2 (IL2) by CD4+ TCRαβ+ cells. 
TCRγδ cells which are the major producers of malaria-induced IFN-γ in vitro accumulate in the peripheral 
blood, where they may release cytokines systematically, contributing more to pathology than to 
protection.  Whereas TCRαβ T-cells express high level of adhesion ligands and disappear from the 
peripheral circulation, presumably migrate to liver and spleen, where they may encounter sequestered 
parasites and be actively involved in parasite killing (14).  
Frequencies and absolute numbers of T-cell subsets (as well as their response to antigenic stimulation) is 
lower in the peripheral circulation during acute malaria, This may be explained by the sequestration of 
activated T-cells expressing the adhesion molecule leukocyte function-associated molecule- 1 (LFA-1) on 
their surface and this lymphopenia, the degree of which correlated with disease severity normalized 
following anti-malarial drug administration (96).  
Both T helper1 (Th1) and T helper 2 (Th2) responses have regulatory functions in human Plasmodium 
falciparum malaria and seem to be required to control the infection, but they need to be adequately tuned 
in intensity and time (13,14,97,98). Type 1 cytokines are important in controlling early parasitemia, 
although they need to be counter balanced later in the infection by a type 2 response which leads to 
antibody production (13).  
1.8.2.1.2. The humoral immune response  
In residents of endemic areas malaria infection induces strong humoral immune responses. Involving 
production of immunoglobulin predominantly IgM and IgG but also of other immunoglobulin isotypes. 
While a large proportion of this immunoglobulin is non-malaria-specific, reflecting polyclonal B-cell 
activation, up to 5% or more represent species as well as stage specific antibodies reacting with a wide 
variety of parasite antigens (83). 
It has been reviewed by Edozien and his coworkers (99) that African serum known to contain more γ-
globulin than Europeans and this, to have a significant relationship with malaria parasitisation. A bulk of 
evidence that antibodies are important in the control of malaria infection comes from the passively 
transferred immune serum. Cohen and his colleagues (100) administered intramuscularly purified γ-
globulins that have been prepared from Gambian adults to Gambian children suffering from acute attacks 
of Plasmodium falciparum malaria. It was found that gamma-globulin has marked effect on both 
parasitaemia and clinical symptoms, although the temperature did not returned to normal before the 7th 
 day and low parasitaemia could still be detected after 9 days in about 30% of the cases. The treated 
subjects were infected again 3 months later, which indicated that the protection was of limited duration. It 
was not clear, how the protection was mediated, but the authors suggested that the antibodies acted either 
on mature intracellular forms or on merozoites.  
Edozien and others (99) confirmed the previous anti-parasitic effect of γ-globulins and the transfer of anti-
malaria immune antibody across the human placenta from mother to fetus, when used Nigerian adult and 
cord-blood γ-globulins for the treatment of children with acute malaria.  
Sabchareon and others (101) studied the effect of intravenous administration of African IgG antibodies 
against Plasmodium falciparum malaria to Thai patients to obtain much faster effect, where the clearance 
of parasites and symptoms was as fast as or faster than with drugs. The effect was stage-specific but non-
sterilizing, since recrudescence occurred after the disappearance of the transferred antibodies. They also 
stated from their data that the antibodies developed after 20 years of exposure to the parasites could confer 
protection on all strains tested. 
It has been indicated that antibodies against sporozoite blood stage and gametocytes mediate protection. 
Antibodies directed against sporozoites inhibited the uptake of Plasmodium falciparum sporozoites into 
culture cells (102).  
Human vaccinated with a B cell epitope of circumsporozoite surface protein (CSP) a major surface 
molecule on sporozoites were particularly protected (103,104).  
Antibodies directed against the blood stages of the parasite could mediate protection in several ways. 
Antibodies against merozoites can block the invasion of merozoites into erythrocytes (105). Cytophilic 
antibodies can opsonize parasites for phagocytosis (106,107), and specific immune serum was found to 
inhibit the dispersal of the merozoites from mature schizonts (108). Antibodies also can obstruct parasites 
attachment to capillary allowing these parasites to be removed by the spleen and liver (109,33,57). 
Antibodies can also mediate anti-toxic immunity against malaria antigens that provoke the production of 
interleukin 1 (IL-1) and tumor necrosis factor (TNF). 
Antibodies against gamete antigens seem to inhibit parasite development in the mosquitoes by several 
mechanisms. Antibodies from immunized animals have been shown to block the fertilization in the 
mosquito mid gut (57). 
In general there is a high degree of cooperation and integration between the innate and acquired immunity, 
where the rate of phagocytosis of an antigen was 4000-fold higher in the presence of specific antibody to 
the antigen than in its absence (93). On the other hand Bouharoun-Tayoun and her colleagues  (110) 
 demonstrated that antibodies that protect human against Plasmodium falciparum blood stages do not on 
their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Druilhe & 
Perignon (1997) hypothesized that the relative amounts of antibodies, monocytes and merozoites can all 
be expected to influence the final range within which the parasitemia is going to fluctuate (111).  
 
1.8.3. Immune suppression during malaria 
Many observations lead to the hypothesis that infection early in life lead to inflammatory immune 
response effective in parasite killing but can cause immuno-pathology. With increasing exposure, immune 
deviation and immuno-regulation may reduce immuno-pathology during infection; with the exception of 
cerebral malaria.  It is clearly in the interest of the parasite and more formally a source of selective 
advantage for strains of falciparum parasites, to develop methods to inhibit immune and inflammatory 
responses, potentially harmful to the parasite and the host (112). Such as impairment of antigen presenting 
cell (APC) function which can be represented by the presence of altered peptide ligand (APL) antagonism 
(113). Macrophages phagocytose intact infected erythrocytes and also extract parasites from recently 
infected erythrocytes, leaving the erythrocytes to continue to circulate (114,115). These crucial defenses 
are undermined and manipulated during malaria infection; the inhibition of macrophage function may be 
in part due to haemozoin. A potential mechanism of inhibition of cellular function by haemozoin is the 
generation of biologically active endo-peroxides-formed by peroxidation of arachidonic acid, where it has 
been found to inhibit macrophage function in vitro (112).  
Intact malaria-infected erythrocytes adhere to dendritic cells (DCs) through CD36 and CD51, inhibit the 
maturation of dendritic cells and subsequently reduce their capacity to stimulate T cells (116,117). After 
interaction with infected erythrocytes, DCs also acquire a capacity to suppress CD8+ T-cell response in 
immunized mice (118). In vitro study demonstrates evidence that natural infection may induce both types 
of antibodies, the protective inhibitory antibodies that inhibit the secondary processing of the 42 KDa 
fragment of the merozoite surface protein 1 (MSP142) and antibodies that block this inhibition by 
competing for binding to merozoite surface (119,120).  
 
1.10. Malaria vaccine 
An alternative hope for malaria control is the development of a vaccine that prevents the majority of naïve 
recipients from developing any clinical manifestation of disease after exposure to Plasmodium falciparum, 
and to prevent the development of severe disease and death in those individuals who do become ill by 
 limiting the effect of blood stage infection. Preventing severe disease and death will require limiting the 
effects of blood stage infection either by reducing parasite replication, reducing cytoadherence and or 
inhibiting the effects of toxic materials released by the parasites.  The vaccine development focuses on 
antigen discovery, immune mechanisms and vaccine delivery system (121). 
 The attempts to develop a malaria vaccine began early in the twentieth century and despite the fast 
advances in science and technology that progress with high optimism no effective malaria vaccine is 
available for widespread human use. This failure may be due to multiple factors where, the Plasmodium 
falciparum have evolved multiple mechanisms of immune evasion at the individual and population level 
including stage specific antigen expression. Where the study done by Bozdech and his colleagues (2003) 
suggested that greater than 75% of the genes expressed during the intra-erythrocytic developmental stage 
of this highly specialized parasitic organism are activated only once (122).  
Still there is a hope for developing a malaria vaccine and this hope is supported by the fact that adults in 
endemic areas develop naturally acquired immunity to disease, and the immunization of mice, non-human 
primates and human volunteers with radiation attenuated sporozoites induce complete sterile immunity 
(123-128). These observations demonstrated that the human host is capable of developing an effective, 
protective immune response against malaria on vaccination 
1.10.1. Potential malaria vaccine candidate antigens 
The development of an effective malaria vaccine depends upon identification of antigens that are targets 
of protective immune responses. The efforts were directed at developing a subunit vaccine, since the 
acquired immunity to Plasmodium falciparum is species, stage, and strain specific (90,91). 
Three approaches have been used for the selection of antigens with vaccine potential. 1) Identification of 
molecules with critical functional roles in the biology of the parasite that expected to be accessible to the 
immune effectors mechanisms. 2) Identification of molecules on the surface of stages in the parasite life 
cycle, which might be exposed to and vulnerable to immune attack.  3) Identification of antigens, which 
are responsible for inducing immune effector’s mechanisms (129). A malaria vaccine aimed at disrupting 
the parasite life cycle at one or more of the 3 stages (sporozoite/pre-erythrocytic stage; asexual 
erythrocytic stage and sexual/sporogonic stage) might be a long term solution (130).   
The complexity of the malaria parasite life cycle implies a considerable complexity of antigens and hence 
problem in selecting the optimal vaccine candidates. It is assumed, however that those molecules which 
are functionally important to the parasite, for example in cell invasion, may be subject to less intra-
specific variation and may be prime targets for vaccine-induced attacks, but the intra-specific antigenic 
 diversity seen in malaria parasites presents a formidable challenge. Blood-stage vaccines against 
Plasmodium falciparum are aimed at preventing complications of disease, such as cerebral malaria or 
anemia. Both Plasmodium falciparum and Plasmodium vivax can cause severe anemia, but only 
plasmodium falciparum causes the many complications of cerebral malaria, hypoglycaemia, metabolic 
acidosis, and respiratory distress. Plasmodium falciparum is responsible for the great majority of deaths 
and, for this reason; most effort has been devoted to Plasmodium falciparum vaccines (131).  
The optimal vaccine is proposed to be multi-stage, multi-immune response i.e. containing antigens from 
the different parts of the life cycle, to induce more than one type of immune response. It was reasoned that 
this might ensure that mutant organisms evading immunity induced against one stage of the life cycle will 
be removed by immunity induced to the next. The vaccine also must be multi-valent, which includes 
multiple epitopes restricted by different MHC molecules (90,129).  
The development of an effective malaria vaccine depends upon identification of antigens that are targets 
of protective immune responses. A variety of promising parasite antigens from several life cycle stages 
have already been discovered and are being developed as malaria vaccine component.  
1.10.1.1. Sporozoite or pre-erythrocytic stage vaccine candidates 
a- Circumsporozoite protein 
 Two proteins have been described to be expressed on the surface of sporozoite known as 
circumsporozoite protein (CSP) and sporozoite surface protein 2 (PfSSP2), which is also known as 
thrombospordin-related adhesive protein (TRAP). Circumsporozoite protein (CSP) has a central area of 
repeated amino acids sequences that are highly immunogenic and are present in all Plasmodium 
falciparum species studied to date. Many studies recommended (CSP) as an excellent vaccine candidate, 
that induces both antibody and cell mediated immunity (132). 
 
b- Liver stage-specific antigen (LSA-1) 
LSA-1 is expressed in infected hepatocytes and contains 17 amino acids repeat, which is immunogenic in 
man (133,134). West Africans produced HLA-restricted cytotoxic T-cells that recognized a nine amino 
acid peptide from LSA-1 in association with HLA BW53. The presence of HLA BW53 correlated with 
protection from severe malaria suggested that immunity to LSA-1 provides some protective immunity 
against severe malaria (132,135,136).  
1.10.1.2. Transmission blocking vaccine 
An option for the design of a malaria vaccine is to aim at the induction of malaria immunity that protects 
 from death and (severe) disease but allows parasite reproduction rate just high enough to ensure natural 
boosting. A transmission blocking vaccine can be an effective tool in the strategy to meet such an 
objective (137). Transmission blocking vaccine aimed at disrupting the sexual development of the parasite 
in the mosquito vectors which leads to the block of the transmission. Pfs 25 is a sexual stage antigen of 
Plasmodium falciparum that is expressed on the surface of zygote and ookinete forms of the parasites. 
Monoclonal antibodies that directed against native Pfs25 could block completely the development of 
Plasmodium falciparum oocyst in the mid-gut of the mosquito vector. Thus Pfs25 has been regarded as a 
potential vaccine candidate for eliciting transmission-block (138).  
Pfs28 is one of the proteins that are relatively late expressed in the sexual cycle and is being present on the 
parasite surface membrane of gametes and ookinetes. 
 Pvs 25 and Pvs28 mice anti-sera raised against Sal I strain of Plasmodium vivax using alum adjuvant 
completely inhibited oocyst development for most natural human isolates of Plasmodium vivax in 
Thailand, where it overcome the genetic polymorphism (139). 
1.10.1.3. Asexual blood stage vaccine candidates 
Plasmodium falciparum express the vast majority of its genes during this intra-erythrocytic stage of the 
parasite life cycle (122). Blood-stage vaccines against Plasmodium falciparum are aimed at preventing 
complications of disease, such as cerebral malaria or anemia.  
The use of asexual blood-stage proteins as malaria vaccines is strongly supported by experimental data 
directly implicating antibodies induced by these antigens in parasite clearance and protection from re-
challenge. These vaccines could complement other vaccines aimed at preventing infection, such as those 
targeted at pre-erythrocytic or mosquito stages of the parasite. Asexual blood-stage vaccines may reduce 
disease by blockade of red blood cell invasion, inhibition of parasite growth in red cells or interference 
with cytoadherence of infected red cells. Clearance of blood-stage parasites is dependent primarily on 
antibody-mediated mechanisms, but CD4 T cells may also play an important role in help for B cells and 
probably have a direct effectors function in the clearance of blood-stage parasites (131). 
1.10.1.3.1. Merozoite surface antigens 
The well characterized merozoite surface proteins (MSP1 and MSP2) of Plasmodium falciparum are 
considered as important vaccine candidates, which are directly accessible to immune attack. Humoral and 
cellular responses to MSP1 and MSP-2 may be of great importance for the induction of protective 
immunity. 
a- Merozoite surface protein 1 (MSP1) 
  It is an integral protein known as MSA1, P195, gp185, PSA and PMMSA. This glycoprotein is processed 
at the time of schizonts rupture to generate the majority of the antigens on the mature merozoite surface 
(140). MSP1 has a molecular weight between 180 and 230 KDa depending on the particular parasite clone 
from which it has been extracted (140-142). Each species of malaria parasite has a single MSP1 gene. The 
gene controlling the expression of MSP1 is found on chromosome 9 of Plasmodium falciparum (143). 
DNA sequence analysis of this gene from a number of in vitro cultured laboratory isolates suggest that the 
MSP1 gene can be divided into 17 blocks that are conserved, semi-conserved or variable. Block 1 and 17 
coding the N and C terminal sequence respectively are the most highly conserved regions. The variable 
and semi-conserved regions exist in only two dimorphic forms. The only exception to this dimorphic rule 
was observed in the polymorphic tri-peptide region at the 5’ end of the gene in block 2. The alleles K1 and 
MAD20 are considered as the allelic prototypes, from which other allelic forms probably have been 
generated by intra genic recombination at the 5’ end of the gene (144). The RO33 form is belonging to the 
same dimorphic group as MAD20 but lacks the N-terminal tripeptide repeat (145). The sequence repeats 
of MSP1 are a minor structural feature of the molecule, and much of the antigenic diversity appears to 
have arisen from intra-genic recombination between two dimorphic alleles (140,144,146). Hui and others 
(147) demonstrated an immunological cross-reactivity between the two gp195 protein and they referred 
this to the recognition of the conserved determinants. 
Post-translational proteolytic process of MSP1 generates fragments of 83, 42, 38, and 28-30 KDa, which 
persist as a non-covalently linked complex on the surface of mature extra-cellular merozoites. Secondary 
processing of the 42 KDa fragments produces a C-terminal 19 KDa fragment (MSP119), which is retained 
on the surface of merozoites throughout invasion of erythrocytes, all other fragments being shed before or 
at this event (148,149). An important role of MSP1 in the invasion process is indicated by the finding that 
prevention of the secondary processing of MSP1 and the shedding of the MSP1 complex result in failure 
of the merozoite to invade the erythrocytes (150). 
The C-terminal of Plasmodium falciparum MSP1 consists of two epidermal growth factors EGF-like 
domains, which is the first protozoan EGF example to be determined (151). MSP119 containing twelve 
positionally conserved cysteine residues (6 in each domain), and this EGF are thought to be required in 
interactions with the erythrocytes (152,153). The immune protection induced by this antigen in different 
animal models appears to be conformation specific as reduction of the disulfide linkage abolishes this 
protective immunity. This fragment is highly conserved in all Plasmodium species, and has been 
 characterized as a major vaccine target antigen since it will be possible to develop a vaccine that induces 
protective immune responses against all Plasmodium falciparum isolates based on this conserved region 
(152). PfMSP119 is highly conserved except for four amino acid residues that subject to dimorphic 
substitutions. In the Wellcome sequence, these four residues are Q in the first motif and K-N-G in the 
second motif, while in the MAD20 sequence they are E and T-S-R, respectively, and the major epitopes in 
the different allelic forms are cross-reactive by human antibodies (154).  Many studies demonstrated the 
antigenicity and immunogenicity of MSP119. Immunoepidemiologic study carried out in West Africa, 
demonstrated that the antibodies to PfMSP119 were shown to provide 40% protection against clinical 
malaria in Sierra Leone. In Gambian children, antibodies to one of the EGF-like motifs of MSP119 were 
strongly associated with resistance to both clinical malaria and high level of parasitaemia (155).  
The role of MSP119 in invasion process is indicated by many experiments, where MSP119-specific 
monoclonal antibody were found to inhibit the erythrocytes invasion (148), and the affinity purified 
antibody to the 19 KDa, C-terminal fragment of MSP1 from malaria immune human serum was found to 
compete with invasion-inhibitory monoclonal antibodies for binding to Pf MSP119 and mediate inhibition 
of parasite growth in vitro (156).  
Infants who were positive for MSP119 were protected against parasitaemia and febrile illness, and those 
negative for IgG had a 10 times greater risk of becoming parasitaemic, suggesting a protective role for 
anti-MSP119 antibodies in infants and pregnant women (157). The role of the antibody response against 
MSP119 in the protection against malaria was claimed in a number of other studies (158-162). However, at 
least one study argued the protective effect of MSP119 antibodies in Ghanaian children (163).   
b- Merozoite surface protein 2 (MSP2) 
MSP2 is a second merozoite surface antigen, integral glycoprotein of 45 KDa. MSP2 is in low abundance 
in the ring stage and therefore is presumably released from the merozoite at the time of invasion, which 
may indicate a role of this molecule in the merozoite attachment to the erythrocytes (164). This antigen 
has been denoted as MSA2, the 45 KDa antigen, the 46-53 KDa glycoprotein, the 35-48 KDa merozoite 
surface antigen, 51 KDa or GP3. It is also a polymorphic glycoprotein (165). The gene coding for this 
antigen is located in chromosome 2 (66). 
Sequencing of the MSP2 gene done by different workers (164,166,167) revealed a pattern of variability 
 that suggested the existence of at least two major family types of MSP2. All MSP2 genes characterized at 
the DNA level can be divided into five blocks of sequence, MSP2 is highly conserved in its N and C 
terminal regions (Block 1 and 5) but contains a more extensive domains of repeats, located centrally 
(Block 3) which vary in number, length and sequence. Non-repetitive variable regions (Block 2 and 4) 
flank the repeats, which define two allelic families called the IC1 or 3D7 (Group A) and FC27 (Group B) 
families. All MSP2 studied were members of these two allelic families, each family being associated with 
characteristic sets of repeats (168,165). When the two alleles of MSP2 group A (IC1 denoted T9/96 
derived from Thai isolate) and group B (FC27, Papua New Guinean isolate) cloned and sequenced, the 
comparison between the DNA and amino acid sequence revealed that the overall homologies are over 
95% among variants in the same sero-group. The similarities between group A and group B variants are 
only 75% and 64% for DNA and amino acids respectively. Within the central region the values are only 
52% and 35% for DNA and amino acid respectively (169). Sequence repeats are a prominent feature of 
the variable central region of the gene. There are more than two types of sequence repeats but one of the 
dimorphic forms of MSP2 is characterized by 12 and/or 32 amino acid repeat, whereas the other 
dimorphic form has much shorter repeats of four or eight amino acids. Different alleles of MSP2 of the 
same dimorphic form and having identical or similar repeats may have different numbers of these repeats 
in the tandem array. The recombination in MSP2 usually occurred in the repeat regions, which although 
very different, have a region of homologous sequence, which presumably facilitated the recombination 
(67). 
Mice vaccinated with diphtheria toxoid conjugated to three octa-peptides from the C and N-terminal, C-
regions of MSP2 of Plasmodium falciparum were found to be protected against lethal inoculums of 
Plasmodium berghei. This shows that the conserved region of MSA2 could form a basis of a malaria 
vaccine when presented in a suitably immunogenic form, thus avoiding the problem of antigenic diversity 
(170). Taylor and his coworkers (171) demonstrated that the antibodies to MSP2 are predominantly of 
cytophilic types (IgG1 and IgG3). IgG3 antibodies to the serogroup A are negatively associated with the 
risk of clinical malaria whereas IgG1 to the serogroup B were associated with an increased risk of clinical 
infection.  
c- Merozoite surface protein 3 (MSP3) 
Is a 48 KDa protein, the antibody from clinically protected subject directed towards specific region of 
MSP3 promotes parasite killing mediated by monocytes.  Purified IgG from protected subjects are 
 effective in antibody dependent cellular inhibition (ADCI) and those directed against MSP3 are 
predominantly cytophilic (172). 
e- Other merozoite surface proteins  
More merozoite surface proteins have been reported such as MSP4, MSP5 (173), MSP6, MSP7 (174), 
MSP8 (175), MSP9 (176) and Apical membrane antigen 1 (AMA) (177). 
 
1.10.1.3.2. Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) 
Since 1965, there have been indications that malaria parasites use the antigenic variation in the strict sense 
to escape host destruction (73). In 1995 many studies established that malaria parasites contain a large 
family of genes for variant antigens (70,71,178).  
These variant proteins are secreted by the parasite and find their way into the erythrocyte membrane, 
where they are concentrated in structure known as knobs. This suicidal action of Plasmodium falciparum 
appears to be required to avoid another death trap, the host spleen, and to avoid this splenic death 
Plasmodium falciparum modifies the host cell by inserting PfEMP1. These proteins make the erythrocytes 
infected with mature parasites attached to vascular endothelium, resulting in their retention in vascular 
bed. Although this trick allows the parasite to avoid splenic death, it now becomes vulnerable to immune 
attack, so the plasmodium uses the antigenic variation of PfEMP1 to mitigate the consequences of this 
attack (73).  
The clonal antigenic variation exemplified by the var multigene family exerts its influence at the level of 
the whole parasite population present in the host. When an effective antibody response is mounted against 
one particular PfEMP1 variant, parasites expressing this variant are eliminated. A few infected RBCs with 
different PfEMP1 proteins on their surface can then expand to dominate the parasitaemia (179). Snounou 
and his colleagues (179) suggest that, the multigene families are a cornerstone in the survival of 
Plasmodium parasites; its success relies on maintaining an infection for lengthy periods despite the 
immune response of the host.  While at the same time limiting their multiplication rate so as to enhance 
the survival of that host. The first evidence of the in vivo switching between variant surface antigens 
(VSA) in human Plasmodium falciparum infection was reported by Staalsoe and others (180).  
PfEMP1 is 200-350 KDa proteins with antigenic variant and adhesive properties, which encoded by the 
var gene. To date, four distinct functions have been attributed to PfEMP1 that contribute to the important 
role of this protein family in malaria disease. These are antigenic variation, cytoadherence, rosetting of 
uninfected erythrocytes and immunoregulatory activities on host immune cells (72).  
 Su and others (70) stress that the var gene products are related to the erythrocyte binding protein (EBA-
175) of Plasmodium falciparum and to the Duffy antigen binding protein (DABP) of Plasmodium vivax 
and Plasmodium knowlesi. The single copy genes for EBA-175 & DABP are conserved and present in all 
Plasmodium line. The common motifs in EBA-175 and var gene products may indicate a common origin 
and have led Su and his colleagues (70) to group the proteins in one super family of Duffy binding like 
(DBL) proteins. Every var gene encodes a high molecular weight PfEMP1 variant composed of tandemly 
arranged cysteine rich domains of ~300 amino acids known as (DBL) domain, and the related cysteine 
rich interdomain regions (CIDRs). Together DBL and CIDR domains account for the majority of PfEMP1 
extra-cellular sequence, in addition to two conserved domains, the C2 domain and the amino terminal 
segment (NTS). Each block of the four major building blocks of the PfEMP1 display regions of diversity. 
Thus PfEMP1 polymorphism encompasses the whole extra-cellular domain. 
The DBL domains are numbered consecutively from the N terminus and have been classified into 5 types 
(α - ε) on the basis of their amino acid sequence, whereas CIDR domains grouped as three distinct 
sequence classes (α, β and γ). A conserved feature of NTS domains is a central block of amino acids that 
is expected to have an alpha helical fold; the second conserved domain is the C2 domain, which found in 
50% of the isolates studied. Both C2 and NTS have globular structure and regions of alpha helical 
structure that is far unique to PfEMP1.  
The DBL and CIDR molecules that possess adhesive properties vary in number between PfEMP1 
variants.  PfEMP1 domain architecture is not random where certain tandem domain association was 
observed (DBLαCIDRα, DBLδCIDRβ, DBLβC2). This conservation may have functional significance for 
PfEMP1 folding, transport or binding activity.  Parasite binding phenotype appears to be a determinant of 
infected erythrocyte tissue tropism that contributes to parasite survival, transmission, and disease outcome 
(72). Infected erythrocytes display multiple and diverse binding properties that vary between clones. DBL 
domains of PfEMP1 have been shown to bind different molecules including intercellular adhesion 
molecule-1 (ICAM-1), chondroitin sulfate A (CSA), complement receptor 1 (CR1), and undefined heparin 
sulfate molecules on the erythrocyte surface, the CIDR1 has been shown to bind CD36 (72).   
The antibodies capable of disrupting rosettes and those agglutinating erythrocytes infected with the late 
stage of Plasmodium falciparum have been reported to correlate with protective immunity (181,182). No 
significant correlation was found between parasite agglutination and response to conserved synthetic 
peptides of PfEMP1 (183). Also no correlation was found between protection and antibody response to 
the conserved PfEMP1 peptide epitope originating from the DBL1 domain of PfEMP1 (41). 
 The antibodies to variable PfEMP1 were found protective against malaria (40,41). The pre-existing anti-
PfEMP1 antibodies (variable) were found to reduce the risk of contracting clinical malaria when 
challenged by novel parasite clones expressing homologous, but not heterologous variable surface 
antigens. Both clinical and subclinical infections induce antibodies against variant antigens, and 
antibodies against several var sero-types are induced during a malaria infection (40).  
1.10.1.4. Anti-toxic and anti-disease vaccine 
Playfair and his colleagues (184) suggested that complete resistance to malaria infection is probably not 
feasible, and that attention should be directed not so much at vaccines designed to eliminate one or other 
stage of the parasite, but rather towards the possibility of an antitoxic vaccine that prevents the serious 
pathological complications of the disease. 
The clinical symptoms of human malaria are mediated at least in part, by the release of tumor necrosis 
factor alpha (TNF-α) by monocytes and macrophages. Monoclonal antibodies were found to inhibit TNF 
inducing factors derived from Plasmodium falciparum infected erythrocytes. This monoclonal antibody 
binds to liposomes containing phosphatidylinositol (GPI) but not to other phospholipids liposomes, 
showing that it recognizes a common phosphatidylinositol-like epitope which has been suggested as a 
suitable immunological target for the prevention or treatment of severe malaria (18). Plasmodium GPIs 
have been also demonstrated to up-regulate expression of endothelial cell surface receptors implicated in 
cytoadherence and to induce hypoglycemia (186). Adults who have resistance to clinical malaria contain 
high levels of persistent anti-GPI antibodies, whereas susceptible children lack or have low levels of short 
lived antibody response, suggesting that anti-GPI antibodies provide protection against clinical malaria 
and thus are likely to be with valuable implication for the development of GPI-based therapies or vaccines 
(187).  
 
1.10.2. Types of vaccine formulations 
Multiple approaches for the development of subunit vaccines have been investigated that include: 
 
a. Recombinant proteins vaccine 
Potential vaccine candidates could be produced in a reasonable amount using recombinant DNA 
technology. Recombinant antigens were found immunogenic and elicit strong protection in monkeys, 
indicating their potential as components of a subunit vaccine (188).  
b. Gene vaccines using viral and bacterial vectors 
 Finding a means of introducing antigenic proteins to the cell cytoplasm to be expressed with MHC 
molecules has become one of the prime challenges in vaccine development. The genes would have to be 
delivered specifically to antigen presenting cells rather than to other cell types to stimulate the T- cells 
(189). Harmless viruses or ones that have been rendered non-replicative in humans or attenuated bacteria 
vector carrying plasmids have been used for delivery of genes derived from different pathogens (189,190).  
c. DNA vaccine 
Wolff and his colleagues (191) provided evidence that plasmid DNA can transfect cells in vivo and hence 
can be regarded as safe alternative of viral and bacterial vectors.  
d. Synthetic Vaccine 
Synthetic peptide vaccines provide several practical advantages when compared to recombinant proteins 
or attenuated bacterial or viral vectors expressing parasite antigens. All components contained in the 
synthetic peptide vaccine are chemically defined and readily available, and provide at least in principal, 
the rapid production of an unlimited supply of immunogens. It is stable and safe compared to the viral or 
bacterial vectors which have the potential for eliciting pathogenic and/or reactogenic complications (192).  
 
1.10.3. Malaria vaccine trials 
A number of malaria antigens reached phase I trial; the apical membrane antigen 1 (177) and MSP3 (193). 
The RTS,S/AS02A is a promising malaria vaccine that reached phase II clinical trial, composed of a 
portion of the circumsporozoite surface protein (CSP) of Plasmodium falciparum linked to hepatitis B 
surface antigen (HBsAg) formulated with the adjuvant system AS02A (194).  RTS,S/AS02A provided 
partial protection against infection in malaria-naïve adults and reduced the risk of clinical malaria, delayed 
time to new infection and reduced episodes of severe malaria over 6 months in African children. The 
vaccine conferred partial protection in African children for at least 18 months, and confirms the potential 
of malaria vaccines to become credible control tools for public-health care (195). 
    
  
 
The objectives 
 
General objectives  
This study is designed to investigate the clinico-epidemiological pattern of severe Plasmodium falciparum 
malaria in an area of low and seasonal malaria transmission. The goal also directed to study the state of 
naturally acquired protection and the impact of the presence of naturally acquired antibodies directed 
against merozoite surface proteins and variant surface antigens on the outcome of infection and 
progression to fatal sort of the disease. 
 
Specific objectives 
1- To describe the clinico-epideiological pattern of severe malaria in Gedarif area, Eastern Sudan. 
2- To measure the antibody response directed towards the conserved C-terminal merozoite surface protein 1 
(MSP119) of Plasmodium falciparum by ELISA. 
3- To measure the antibody response directed towards the two alleles of the polymorphic Plasmodium 
falciparum merozoite surface protein 2 (MSP2) by ELISA.  
4- To measure the antibody response directed towards different variants of Plasmodium falciparum 
erythrocyte membrane protein-1 (PfEMP-1) using flow cytometry. 
5- To identify the patterns of the immune response among severe and uncomplicated Plasmodium falciparum 
malaria patients compared to malaria free volunteers. 
 
 MATERIALS AND METHODS 
 
2.1. Study area, study design and samples 
2.1.1. Study area  
This study was carried out over two successive malaria seasons in the period between September 
2000 and January 2002, in Gedarif Hospital. Gedarif town (350 - 400 thousand inhabitants) is 
situated on the Sudanese Savannah, at an altitude of about 600 meters above sea level; 350 km 
from the capital, Khartoum. The epidemiology of the febrile uncomplicated malaria episodes in 
the area has been reported before (40). The area is mesoendemic for Plasmodium falciparum 
malaria which is the predominant malaria species in the area (98%), Plasmodium vivax and 
Plasmodium malariae occasionally seen (2). Malaria in the area is highly seasonal, and follows the 
annual June–October rains; the seasonal incidence of malaria varies considerably from year to 
year (196). Anopheles arabiensis is the sole malaria vector in the area. The entomological 
inoculation rate (EIR) in Gedarif has not been measured, but was found to be very low and 
difficult to measure by conventional methods in the surrounding villages (197).  
2.1.2. Study design  
Patients reporting to Gedarif hospital were seen by medical doctors at an outpatient clinic. Blood 
slides were prepared from suspected malaria patients and examined for the presence of malaria 
parasites. Based on clinical assessment, patients with severe falciparum malaria were admitted and 
patients with uncomplicated disease were treated as outpatients. All patients who satisfied the 
WHO criteria of severe malaria were enrolled in the study, and control groups (uncomplicated 
malaria and healthy donors) were matched for age, gender, residence and etc. Households and 
relatives were being a priority in the selection of the two control groups. Certain investigations 
were routinely done for the patients with severe malaria e.g. blood glucose level (electronic 
glucometer, accu trend™), blood insulin measured by radioimmunoassay (kit IMK-414, Beijing, 
China; Morgan and Lazarow, 1962), urine general and complete haemogram. Other diagnostic 
investigations were also done, each was selected based on the clinical presentation of the patients 
e.g. chest X-ray, blood and spinal fluid culture, serum/plasma creatinine, lactate, urea, electrolytes 
and etc. The results and the clinical data were entered into a data base program. Severe malaria 
patients were treated with the standard dose of Quinine sulphate; patients were discharged from 
 hospital after clinical improvement and the ability to continue the treatment orally at home under 
our supervision. Patients were followed up, clinically and parasitologically up to day 28 after 
diagnosis, and were advised to visit our malaria clinic if symptoms recurred thereafter.  
The consent 
Informed consent was obtained from severe, uncomplicated malaria patients and malaria free 
donors. In case of children or comatose patients the consent was obtained from parents or 
guardians (a copy of the consent is attached in the appendix). 
This study had national ethical clearance and national endorsement from the ministry of health, 
Sudan. 
2.1.2.1. Malaria definition and diagnosis  
A patient was defined as suffering from malaria if he/she complained of fever or had body 
temperature measured with an oral probe of > 37.5°C plus microscopically detected asexual 
parasitemia. 
For diagnosis, thick and thin blood smears were prepared, stained with Giemsa and examined for 
malaria parasites under a magnification of x1000. Films were considered negative after 
examination of 200 thick smear fields without detection of parasites. For positive films, the 
parasites were counted per 300 leukocytes and standardized per one micro liter of blood (198).  
2.1.2.2. Characterization and grouping of patients with severe malaria 
Having the clinical information (symptoms and signs) and the laboratory results available the 
patients were allocated to the different categories of severe malaria according to the WHO criteria 
for severe and complicated malaria (8), one or more of the features in the presence of asexual 
parasitemia. The patients with severe anemia, had normocytic normochromic anemia with 
haematocrit <15% or haemoglobin <5 g/dl. Those with cerebral malaria were in unarousable coma 
persisting for at least 30 minutes, while convulsions diagnosed when patients had generalized 
convulsions, at least two/24 hours despite cooling. The hypotension was defined as systolic blood 
pressure <50 mmHg in children (1-5 years) or < 70 mmHg in adults), with cold clammy skin. 
Patients who had more than one type of complications e.g. cerebral malaria and severe anemia 
were categorized separately.  
Patients were treated immediately with antimalarial and other needed drugs. Patients with SMA 
were further treated with cross-matched, infections-screened blood infusion.  
  
2.1.3. Samples collections and storage 
2.1.3.1. Plasma and parasitized red blood cells (PRBC) separation and storage 
Five to seven ml of blood samples was collected in EDTA vacutainer tubes. The samples were 
centrifuged for 10 minutes, the plasma separated and kept frozen at – 20 0C. For the PRBC, equal 
amount of freezing solution (sterile mixture of 3% sorbitol, 28 % glycerol and 0.65% NaCl in 
water) was added (after puffy coat removal), mixed and immediately kept in liquid nitrogen.  
Blood samples were spotted on filter paper and sealed separately in plastic bags for PCR 
investigations.  
2.2. Measurement of antibody response directed against MSP119 and MSP2 by 
indirect ELISA. 
Recombinant proteins representing the 19 kDa, C-terminal fragment of merozoite surface protein 
(MSP119) and two antigens representing the full length of group A and group B alleles of 
merozoite surface protein 2  (Group A, denoted T9/96 13/14 and group B, FC27 denoted GF/88), 
and glutathione-S-transferase (GST) protein were used.  
The recombinant antigens were prepared according to the method that has been described by 
Ranford-Cartwright and others (199), where the gene representing these proteins were expressed 
in Escherichia coli as fusions to the C-terminus of glutathione-S-transferase (GST) of 
Schistosoma japonicum using the pGEX vectors, which permit the purification on a glutathione 
column.  
The method that has been described by Cavanagh and others (149) was used with slight 
modification. The wells of the 96 well plates were coated with 100 µl of recombinant protein 
fused to glutathione-S- transferase (GST). 16 ng of MSP119, 50 ng of T9/96 13 / 14 isolate of 
(group A) of MSP2, 25 ng of GF 88 full length of FC27 (group B) of  
 
MSP2, and 50 ng of GST in coating buffer (carbonate buffer pH 9.4- 9.6) as determined by 
checkerboard titration. The plates incubated for three days at 4°C., the wells were washed five 
times with the washing buffer that composed of phosphate buffered saline with 0.05 % Tween 20 
(PBS-Tween-20). Unoccupied protein binding sites on the plate were blocked with 200 µl per well 
 of blocking buffer (1% skimmed milk in washing buffer) for five hours at room temperature, 
again the wells washed five times. Sera diluted 1:500 in blocking buffer; (100 µl/well) were added 
to duplicate antigen-coated wells and incubated over night at 4°C.  After five washes, the wells 
were incubated for three hours at room temperature with 100 µl (1:5000) of the conjugate 
(Horseradish peroxidase-conjugated to rabbit anti-human IgG, specific for gamma chain 
(HRP/IgG) DAKO A/S, Denmark). 
The plates were then washed again and incubated for 10 minutes with 100 µl of the substrate 
buffer. The reaction was stopped by the addition of 20 µl of 2M H2SO4. The optical densities were 
measured at 492 nm, using the ELISA reader (Labsystems Multiskan MCC/340). The inter-plates 
variations were controlled by the introduction of pool positive and negative sera in each plate. The 
optical density value for each serum sample was calculated by subtracting the mean optical 
density value of wells containing control GST protein alone from the mean optical density value 
of wells containing antigen-GST. 
Cut off values at which binding of antibodies was regarded as significantly above background 
were calculated as the mean plus three standard deviations of optical density readings obtained 
with sera from Danish donors with no history of exposure to malaria. 
 
2.3. Measurement of the antibodies directed against Plasmodium falciparum 
erythrocyte surface protein 1 (PfEMP1) 
2.3.1. Parasites 
Thirty five parasite isolates were thawed and cultured as described before 
(200,201), 22 parasite isolates were successfully grown and used, they were 
obtained from 7 cerebral malaria (CM), 4 severe malarial anemia (SMA), 1 
convulsion-associated malaria (CAM) and 10 uncomplicated malaria (UM) patients.  
2.3.2. Plasma 
A total of 215 plasma samples used were obtained from 5 groups of donors. 139 
plasma samples were collected at the time of diagnosis and before treatment; 75 
from patients with severe malaria, and 64 from patients with uncomplicated 
malaria. The other sets included; 17 samples from cerebral malaria patients at 
convalescence (day 28), 33 samples from Sudanese malaria–free donors, and 26 
 samples from Tanzanian patients with malaria. The experiment was controlled by 
11 Danish (not known to be exposed to malaria) plasma samples, and a pool of 
African (Gomoa) hyperimmune plasma samples from African adults was used in 
duplicates for 6 serial dilutions for semi quantitative scoring of the level of 
immune response, where, the values above the cut off point and the 1:16 
dilution gave the rank of 1, above 1:16-1:8 gave the rank of 2, above 1:8-1:4 
gave the rank of 3 and so on until those above 1:1 dilution where they gave the 
rank of 6.  
The mean of the 11 Danish plasma readings plus two standard deviations was 
regarded as the cut off value above which, a sample can be regarded as positive 
for PfEMP1 antibodies for each parasite isolate.  
2.3.3. Long term In vitro culture of Plasmodium falciparum from cryo-
preserved patient isolates 
The liquid nitrogen freezed infected red blood cells were thawed in a 37 0C. water-bath, the tube 
then spinned at 2000 rpm (600g) for 8 minutes, immediately after thawing the supernatant 
discharged and 500 µl of thawing solution (3.5% NaCl) was added and spinned for 8 minutes, 
supernatant removed and 1 ml of pre-warmed culture medium (500 ml RPMI-1640 supplemented 
with 25 mg Gentamycin, 91.6 mg L-Glutamine, 2.5 g Albumax II, 10 ml normal human serum 
and 10 mg hypoxanthine)  was added, spinned and supernatant removed, the washing was 
repeated until the supernatant became clear (maximum 3 washes). The pellet was added to a 50 ml 
culture flask; 6 ml of culture medium and 200 µl of washed uninfected packed cells (type O Rh- or 
Rh+) were added.  The culture flask was then flushed with gas mixture of 2% O2, 5.5 % CO2, and 
92.5 % N2 through 0.2 mm filter unit at 1.5 - 2 bar pressure for 30 seconds. The flask was 
incubated at 37 oC. Twenty four hours later the culture medium was changed and the parasitaemia 
was estimated (slides were prepared and stained by 10% Giemsa stain). The culture monitoring 
was proceeded every 48 hours with medium change and parasite count and when the parasitaemia 
start to increase the culture suspension was removed to a 250 ml culture flask, washed uninfected 
erythrocytes and more culture medium were added and flushed with the gas mixture for 90 
seconds. The monitoring was proceeded every 48 hours until a mature form of parasite with 
parasitamia of 2% or more reached. 
 
2.3.4. Magnet activated cell sorting (MACS) 
 Mature–form of Plasmodium falciparum cultures were enrichmed by magnetic selection, a 
method that has been described by Staalsoe and her colleagues (39) that relies on the 
paramagnetic properties of the parasite metabolic waste product hemozoin that firstly been 
described  by Paul and others in 1981 (202). The VarioMACS magnet (Miltenyi 
Biotec), with size CS column was used. The three-way valve was assembled at the bottom 
of the column; the tip of the outlet needle was cut by a pair of nippers and then mounted on the 
downward arm of the 3-way valve. The column was mounted in the VarioMACS magnet and the 
3-way valve was adjusted to allow flow through its side arm, and then the column was filled with 
phosphate buffered saline with 2% fetal calf serum (PBS2) by injecting the fluid into the side arm 
of the valve using a 20 ml syringe. The 3-way valve was opened to allow flow from the column 
through the outlet needle and when there was no PBS2 left in the loading chamber above the 
column the suspension of the infected red blood cells was added. The passing solution that 
contains the uninfected red blood cells or those infected with immature form of parasites was 
collected as waste. The column was washed with PBS2 until no more red blood cells were seen in 
the effluent (change from red to absolutely clear). Five ml of PBS2 was added to the upper 
chamber and a 20 ml syringe filled with 20 ml PBS2 was mounted on the top of the column via 
the top adapter, the column was then removed from the magnet and a syringe used to flush the red 
cells infected with the mature form of the parasites that have trapped inside the column through 
the outlet needle.  
This method was used to enrich in vitro Plasmodium falciparum cultures to > 80 % late stage 
infected erythrocytes. Parasites enriched in this way are completely unaltered and fully viable 
(Figure 2.1A & B). 
 
 
 
 
Figure 2.1A 
               
 
 
 
  
 
 
 
Figure 2.1B 
                
 
 
 
 
 
 
 
 
 
 
 
 
Cleaning the column: for re-use, the column was rinsed by passing 3*20 ml PBS followed by 
3*20 ml distilled water and finally by 3*20 ml 70% ethanol through the column by using a 20 ml 
syringe through the top adapter of the column. The column was dried carefully by blowing 
compressed air through the column for several minutes. 
 
Counting of red blood cells infected with mature parasites 
The cells infected with late trophozoites and schizonts that have been enriched with MACS were 
counted in a Neubauer chamber. The mature parasites were centrifuged for 8 minutes at 2000 rpm 
and the supernatant discharged and the pellet was re-dissolved in 5 ml PBS2. Twenty five 
microlitre of the cells was diluted to 500 µl with PBS2 and the number of cells was counted in 
4*16 fields using the Neubauer chamber and then the number of cells per milliliter of buffer was 
counted 
Fig. 2.1A: P.falciparum parasite (Gedarif ) from an in vitro culture showing different 
developmental stages of rings and late stages.   
Fig. 2.1B: RBCs with late stage P. falciparum parasites from Gedarif area after it had 
been in vitro cultured and enriched to late stage (schizonts and trophozoites) by MACS  
           Number of cells * dilution factor * 1000 µl/ml      = Cells/ml 
                                       4 * 0.1 µl 
Dilution factor = 20 
4 = Number of Neubauer chamber squares counted 
0.1µl = volume /square  
 
2.3.5. Analysis of plasma antibodies to variant surface antigens by fluorescent 
activated cell sorter (FACS) 
The FACS analysis was used for the measurement of antibodies (Abs) directed 
against P. falciparum variant surface antigens (VSA), the full protocol was 
described before. The antigens recognized by this method were reported strain 
specific and their molecular weight are in the range previously described for 
PfEMP1 antigens (39). 
The number of the erythrocytes infected with late stage of Plasmodium falciparum was adjusted to 
2.5*106 erythrocytes/ml with PBS2, and labeled with 20 µl ethidium bromide (0.1 mg / ml in 
PBS) per ml of erythrocyte suspension. Five-microlitre plasma were placed in FACS tubes then 
100 µl of ethidium bromide labeled infected erythrocytes were added and incubated for 30 
minutes at 5 0C. Then 3 ml of PBS2 were added to each tube, centrifuged for 8 minutes at 2000 
rpm, supernatant discharged and other 3 ml PBS2 were added, centrifuged and supernatant 
discharged. After the second wash the precipitate were resuspended in 100 µl of Goat anti human 
IgG antibody (1:250 in PBS2) and incubated for 30 minutes at 5 0C. The tubes then washed twice 
with PBS2 and the pellet was resuspended in 100 µl of Rabbit-anti goat-IgG - FITC (Green 
fluorescence diluted 1:25 in PBS2) and incubated for 30 minutes at 5 0C. 
The tubes then washed once and the precipitate was resuspended in 200 µl PBS2. The tubes were 
kept overnight at 5 0C. and then analyzed by flow cytometer.  
The flow cytometer setting was adjusted to achieve a clear separation of uninfected (ethidium 
bromide negative) and infected (ethidium bromide positive) erythrocytes in an FSC/ethidium 
bromide dot plot. Data acquired and stored on FSC (forward scatter), SSC (side scatter), FL1 
(FITC), and FL2 (ethidium bromide). FACS data were analyzed by Win List software packages. 
A gate was set around late-stage infected erythrocytes (blank tube without plasma) in an 
FSC/ethidium bromide diagram plot. The FITC fluorescence of the cells within this gate was used 
 to quantify the antibody response of variant surface antigens, which expressed as mean/median 
fluorescence (Figure 2.2). Blank tube, Danish plasma, serially diluted positive plasma, Tanzanian 
plasma (hyper-endemic area) and all study samples (Sudanese patients’ and malaria free plasma) 
were assayed on the same day for each parasite isolate. 
Cut off values at which the samples were regarded as antibody positive were calculated as the 
mean fluorescence plus two standard deviations obtained with plasma from Danish donors.  
 
2.4. Statistical analysis 
The statistical package for social sciences (SPSS 10.0 for windows) software was used for the 
analysis of the clinical and other characteristics of malaria patients and the control group’s data. 
For comparison of groups, first the distribution of data was tested for normality by descriptive 
statistics, normally distributed data analyzed by independent samples T-test, and when normal 
distribution was violated, data transformed by computing, and then analyzed. Uncorrected 
distributions were analyzed using non-parametric tests. Kruskal-Wallis test was used for 
comparison between clinical subgroups of severe malaria. The quoted levels of significance allow 
for post-hoc testing using Scheffe's method (Comparison of age, hemoglobin and blood glucose 
level between individual complications) or the Least Significant Difference (LSD) method 
(parasite count between individual complications).  
The SigmaStat statistical software, version 2.03, was used in analysis of data of merozoite surface 
proteins (MSPs) and Plasmodium falciparum erythrocyte membrane protein (PfEMP1).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the prevalence of anti-MSP antibodies in different study groups, Chi-square test and Fisher 
Exact Test were used. The t-test and Mann-Whitney Rank Sum Test were used for comparison 
between malaria and malaria-free donors and between patients with UM and SM with regard to 
the plasma level of antibodies (donors with positive response) and for the number of MSP 
antigens recognized by the different study groups. For comparison of plasma levels of antibodies 
and number of merozoite surface protein antigens recognized, between the SM, UM and MF 
donors and between the subgroups of SM, One Way Analysis of Variance (ANOVA) and One 
Way ANOVA on Ranks were used.    
For variant surface antigens (VSA) reactivity, the descriptive statistics mean 
and standard deviation were calculated. For comparison between the reactivity 
of plasma obtained from the different subgroups of severe malaria patients, and 
Figure 2.2. FACS histogram results representing the antibody response 
of blank sample (Bl), 11 Danish plasma samples, Pool positive plasma in 
6 dilutions and 2 severe plasma samples from Gedarif area directed 
against PfEMP1 of a severe Plasmodium falciparum isolate (SG93). 
 to compare between the recognition rate of isolates from CM, SMA, and UM 
patients t-test, Chi-square test and One Way Analysis of Variance (One Way 
Anova) were used. To test the correlation between levels and prevalence of VSA 
antibodies and that between prevalence of VSA antibodies and the age of plasma 
or parasite donors Pearson Product Moment Correlation  
was used.  
 RESULTS 
 
3.1. Epidemiology of severe Plasmodium falciparum malaria 
3.1.1. The frequency of acute uncomplicated and complicated malaria  
The total number of patients clinically suspected of malaria for whom blood smears were taken and 
examined were 16 606 and among them, 2 488 patients (15%) were found to be parasitemic (table 3.1). 
Plasmodium falciparum was the causative agent in 98.88%, while Plasmodium vivax, Plasmodium 
malariae and Plasmodium ovale, accounted for 0.64%, 0.44% and 0.04% of all malaria infections, 
respectively. No mixed infections were detected. Based on clinicians' decision 252 malaria patients 
were hospitalized, and 110 (4.4%) fulfilled the WHO criteria for severe malaria and were included in 
the study. Seven patients died, all with cerebral malaria. The mortality rate was 0.3% of all malaria 
infections, 6.4% for all severe cases of malaria and 38.9% for patients with cerebral malaria. 
 
Table 3.1. Clinical categorization of patients presented with malaria-like symptoms to the malaria 
clinic at Gedarif Hospital, in the period, from September 2000 to January 2002. The patients died of 
severe malaria were all had cerebral malaria.   
A
Pati
Rate of malaria Uncomplicate Proportion of sever
Severe m
death r
 
166
 
15% 
(2488/166
95.6%
(2378/24
4.4% 
(110/2488)
6.4%
(7/11
 
 
3.1.2. The frequency of the different types of severe complications   
The WHO criteria for severe malaria were used to classify malaria patients as uncomplicated and 
severe. The clinical presentations of patients categorized as having severe malaria are shown in figure 
3.1. Severe anemia (50 patients) was most commonly found and accounted for 45.5% of the severe 
malaria cases. Cerebral malaria was found in 16.4% (18 patients) of the patients. The rest had 
convulsions, hypotension or a mixture of above manifestations. There was a tendency that a higher 
 percentage of patients had anemia during the second malaria season, but the difference between clinical 
presentations in the two years was not statistically significant. Six patients had more than one type of 
complication; two patients with cerebral malaria were also anemic, while four severely anemic patients 
also presented with convulsions. Other complications, like respiratory distress syndrome, renal failure, 
and bleeding abnormalities (thrombocytopenia) were not recognized during the study. There was no 
difference in the clinical presentations in females and males.    
 
 
 
3.1.3. Age distribution of severe and mild malaria   
Uncomplicated and severe malaria affected both children and adults, but as seen in figure 3.2, small 
children between two and four years constituted a much higher percentage among patients with severe 
malaria compared to patients with uncomplicated disease.  
 
Twenty seven malaria patients (14 females and 13 males) were above 12 years of age and constitute 
24.5% of the severe malaria patients. The incidence of severe malaria in males and females was (1:1).    
Figure 3.1. Symptoms in the 110 patients admitted to Gederif Hospital, Eastern Sudan 
and fulfilling the WHO criteria for severe malaria, the patients were admitted over a 
period of two years.    
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3.1.4. Characterization of patients in the different categories of severe malaria  
The mean age in years (mean ± SD) varied markedly between the different categories of patients with 
severe malaria. Malaria patients with anemia or convulsions aged 5.6±7.7 and  5.9±5.3 years 
respectively were infants and small children, patients with cerebral malaria aged 14.1±13.4 were older 
children and young adults, whereas hypotensive group aged 35.2±12.1, were adults (figure 3.3a). The 
mean parasite count was highest in patients with convulsions and in this group the parasitemia was 
significantly higher than in patients with hypotension or anemia (figure 3.3b). The group of patients 
with severe anemia by definition had low levels of haemoglobin, but the other groups did differ with 
respect to this parameter (figure 3.3c). The  
Figure 3.2. Age distribution of patients with severe malaria (n=110, white dots) and 
with uncomplicated malaria (n=1 537, black dots) in Gedarif Hospital, eastern Sudan 
(period 2000 to 2002). 
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 Figure 3.3: Comparison 
between four groups of 
patients with severe malaria 
(anemia, convulsions, cerebral 
malaria and hypotension) 
admitted to Gedarif Hospital; 
in the following;  
a. Age in years (mean ± 95% 
confidence interval, CI) 
 b. Parasite count (mean ± 
95% CI) at diagnosis (day o) 
and before treatment, 
c. Hemoglobin level (mg/dl, 
converted to percentage), 
mean ± SD, at diagnosis and 
before treatment,  
d. Random blood glucose 
level, mean ± SD, at diagnosis 
and before treatment. 
Horizontal lines with P-values 
span between clinical groups 
with significant differences 
 mean blood glucose levels at diagnosis and before treatment, was higher in patients with cerebral 
malaria than in patients with anemia (figure 3.3d), but did not differ significantly between the other 
groups.  The white blood cell (WBC) count was highest in patients with cerebral malaria (6 876.5± 4 
556, mean ± SD), but the differences between the groups were not statistically significant.   
3.1.5. Comparison between fatal and non-fatal severe malaria    
Seven patients with cerebral malaria died despite treatment. The characteristics of these patients are 
shown in (table 3.2). Two of the patients were adults and the remaining were children between 5 - 11 
years. The duration of symptoms before admission varied between two to seven days. The mean (±SD) 
haemoglobin and the mean blood glucose levels were higher in patients who died of severe malaria 
than in the survivors (p=0.035 and p<0.001, respectively, T-test). The differences in glucose levels 
were not reflected in the insulin levels, which were comparable between the groups, although insulin 
level in fatal malaria was above the normal physiological range (4.0 to 16.8 mIU/L).  
 
3.2. The antibody response against the conserved and polymorphic antigens of the 
merozoite surface proteins (MSP119, MSP2A and MSP2B) 
3.2.1. Characteristics of donors   
Patients with SM (n = 109, mean age ± SD in years (yrs), 10.6 ± 13.1), and a 
comparable number of patients with UM (n=114, 13.5±13.1 yrs) and malaria free 
donors (MF) (n=117, 12±12.8 yrs) were included in this part of the study. The mean 
age, age range and gender distribution, were comparable between the groups, see 
table 3.3. Patients with SM had either severe malaria anemia (SMA) (n=49, 5.6±8 
yrs), convulsions associated malaria (CAM) (n=23, 5.9±5.2 yrs), cerebral malaria 
(CM) (n=18, 14.1±13.2 yrs) or with hypotension HTN (n=13, 35.2±12.1 yrs), while 6 
patients had multiple complications (3.3±1 yrs). Seven patients died within the 
first three days after hospital admission, they were all with CM.   
3.2.2. Recognition of merozoite surface protein (MSP)  
The frequency of pre-existing antibodies in plasma of all donors (n=340) at the time of malaria 
diagnosis (D0) against the MSP antigens, showed a consistent differences in recognition of the three 
antigens. The MSP119 was the most recognized Ag (49.8%, 166/333), followed by MSP2A (41.6%, 
137/329), then MSP2B (37.2%, 123/331), in all conditions whether the data was pooled or each group 
or subgroup of samples were considered separately the differences were not significant. On the other 
hand there was strong statistically significant correlation in recognition of the three antigens i.e. the 
 plasma that recognized one antigen tends to recognize the other antigens and vice versa.    
 
 
 
Table 3.2. Levels of variable parameters (parasitological, hematological and biochemical) in 
individuals who died of severe malaria, at Gedarif Hospital, eastern Sudan, and comparison of the 
mean values of these parameters between fatal and non-fatal severe malaria groups   
Age (years Symptoms
duration# 
Parasite coun
(parasite/µl) 
Hemoglobi
level (%) 
WBC 
(cell/µl)
Blood glucos
(mg/dl) 
Insulin level
(mIU/L) 
11/male 3 days 4350 ND ND 219.6 32.6 
35/male NK 180000 92 1900 122.0 9.0 
09/female∗ 4 days 96000 60 4000 246.6 20.3 
05/male 3 days 114000 65 11600 102.6 4.1 
55/male 5 days 4800 46 4600 311.0 25.0 
10/male 7 days 3150 ND 3500 149.4 ND 
06/female 2 days 42000 40 11000 111.6 ND 
RI 18.7 
 
63471± 
68590 
60.6± 
20.3 
6100±
4131 
180.4± 
79.7 
18.2± 
11.6 
 
RII 10.5 
  
37940± 
66741 
42.18± 
18.3 
5790±
2962 
94.3± 
29.9 
13.8± 
12.7 
P-value  0.226 0.035 0.885 <0.001 0.406 
WBC: white blood cell count. NK: not known.   RI: Row I; mean ± SD of measured variables in 
patients with fatal SM.  RII: Row II; mean ± SD of measured variables in patients with non-fatal SM.       
# before admission.       ∗  The patient received a drip of 5% dextrose in saline, before blood sampling      
 
 
 
 
 
Table 3.3.  Characteristics of the different groups of volunteers studied, plasma collected during two 
successive transmission seasons 2000-2002 from Gedarif, eastern Sudan 
     
Donors Number Gender Age in years Statistical differ
 Males% mean±SD & range 
Severe malaria 
 
109 49.1% 10.6±13.1 
(0.9 – 55) 
 
Uncomplicated m
 
113 
 
52.6% 
 
13.5±13.1 
(0.7 – 61) 
 
Malaria-free don
 
117 
 
49.6% 
 
 
12±12.8 
(1 – 70) 
 
 
 
No s
differences 
 
 
 
3.2.3. The relation between the age and the prevalence of MSP antibodies 
The donors were divided into 6 age groups (figure 3.4.), based on the physiological development; 
infants (1 year or less), young children (>1 – 5 yrs), older children (>5 – 10 yrs), adolescents (>10 – 15 
yrs), adults aged (>15 – 45yrs), and older adults (>45 Y). A donor was considered as responder to MSP 
antigens if his/her plasma contains antibodies to at least one of the three tested antigens, (MSP119, 
MSP2A and / or MSP2B). Accordingly, the prevalence of the antibodies in each age group (proportion ± 
95% CI) was; 18.2±18.2%, 52.5±8.9%, 68.3±9.1%, 80±14.3%, 89.2± 7.5% and 100%, respectively. 
Thus, the prevalence of plasma anti-MSP antibodies in all study population was increased with 
increasing age. When the middle age of each age group was correlated with the anti-MSP antibodies 
prevalence rate, statistically significant positive correlation was found (CC=0.836, P=0.0384, Pearson 
Product Moment Correlation).  
  
 Age groups (years)
pr
ev
al
en
ce
 o
f a
nt
i-M
S
P
s 
an
itb
od
ie
s 
(%
)
0
20
40
60
80
100
120
 
 
 
 
 
 
 
3.2.4. The antibody response against MSP antigens: comparison between apparently healthy 
malaria-free donors and malaria patients 
The apparently healthy malaria-free donors (n=117) had negative blood smears for malaria  
parasite by microscopy. However, using PCR, 22 (18.8%) patients were found to have had 
asymptomatic sub-microscopic parasitemia, half of them had anti-MSP antibodies (50%), among the 
remaining 95 donors 44 donors had anti-MSP antibodies (46%). The prevalence (proportion±95% CI) 
of MSPall antibodies in this group of donors was 47±9% (table 3.4).  
The prevalence of MSPall antibodies in malaria patients (uncomplicated and severe) (n=223) was 
77.1±5.5%, which was significantly higher than in MF donors, (p<0.001, Chi-Square).  
Figure 3.4. The prevalence of Abs against MSP119, MSP2A and MSP2B  Ags (proportions 
± 95% confidence interval), in the different age groups of all donors together; patients 
with malaria (severe and uncomplicated) and malaria-free donors (n=339). The age 
grouping was based on physiological development (infants 0-1, young children >1-5, 
older children >5-10, adolescents >10-15, adulthood >15-45, older adults >45 year). 
0-1         >1-5      >5-10      >10-15    >15-45      >45. 
  
Table 3.4. The malaria-free donors (negative control) were apparently healthy, and had negative blood 
smears for malaria parasite, as seen by microscope. The table shows the donors with parasitemia 
(detectable by PCR) and with anti-MSP antibodies (against any of the following MSP antigens: 
MSP119, MSP2A and/or MSP2B)  
 
   Malaria-free donors 
 
PCR positive 
 
PCR negative 
 
Total 
MSP positive ELISA 11 
50%(11/22) 
44 
46.3% (44/95) 
55 
47% (55/117) 
 
MSP negative ELISA 11 
50%(11/22) 
51 
53.7% (51/95) 
62 
53% (62/117) 
 
Total 22 95 117 
 
 
 
The prevalence of the individual MSP antibodies; MSP119 antibody, MSP2A antibody and MSP2B 
antibody, in MF donors were; 32.5 ± 8.5, 19.7±7.2, 25.6±7.9, respectively, which were significantly 
lower than in malaria patients (57.8±6.5, 44.8±6.6, 48 ± 6.5, respectively), (all p=<0.001, Chi-Square) 
(figure 3.5A.). The median number of MSP Ags (n, [25% - 75% 
percentile]) recognized by the malaria patients was 2, [1 – 2], which was significantly higher than in 
MF donors (0, [0 – 1]), (P = <0.001, Mann-Whitney Rank Sum Test). The plasma level of MSP119 
antibody and MSP2A antibody, was significantly higher in malaria patients (SM and UM) (0.739 and 
0.641, respectively) than MF donors (0.518 and 0.449, respectively) (p= <0.001, t-test, and p=0.002, 
Mann-Whitney Rank Sum Test, respectively). While there was no significant difference in MSP2B 
antibody levels between the malaria patients (1.084) and MF donors (1.107) (p=0.858, t-test) (table 
3.5). 
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Figure 3.5. The prevalence of antibodies against individual MSP antigens; MSP119, 
MSP2A, MSP2B or any of the three antigens (MSPall), proportion (%) and 95% confidence 
interval (CI). A: Comparison between malaria-free donors (dark bars) and patients with 
malaria (both uncomplicated and severe malaria), (light bars). B: Comparison between 
patients with severe malaria (dark bars) and uncomplicated malaria (light bars), the 
differences were all significant although in MSP2A and MSP2B bars; there was slight 
overlap for CI.  
  
Table 3.5. The plasma level of antibodies in individuals with positive antibody response (above the cut 
off point) directed against different MSP antigens among the 3 different study groups: a comparison 
between malaria-free donors (MF), uncomplicated malaria (UM) and severe malaria (SM) patients.    
 
The level (mean/median) of anti-MSP antibodies The antigens 
MF UM SM P-value  Statistical test  
 
MSP119 
 
MSP2A 
0.518 
 
.449 
0.728 
 
.672 
0.76 
 
.549 
<0.001 
 
<0.001 
 
1Tukey Test 
(mean) 
2Dunn,s Method 
MSP2B 1.107 1.128 1.018 >0.05 ANOVA 
(mean) 
      
 
1 = One Way Analysis of Variance (ANOVA) 2 = Kruskal-Wallis, One Way Analysis of  
Variance on Ranks    
Note: values in italic were significantly lower than bolded values. 
 
 
3.2.5. The antibody response against MSP antigens, comparison between patients 
with uncomplicated and severe malaria 
The prevalence of MSP119 antibodies and MSPall antibodies, was significantly higher in patients with 
UM (68.1%±8.6 and 86%±6.4, respectively) compared with SM patients (48.1±9.5 and 67.9±8.8, 
respectively) (p=0.004 and p=0.002, respectively, Chi-Square). The prevalence of MSP2A antibodies 
and MSP2B antibodies were significantly higher in patients with UM versus SM patients (56.1±9.1 vs 
41.7±9.5 and 53.6±9.2 vs 37.4±9.2, respectively) (p=0.048 and p=0.023, respectively). For the last 2 
antigens, although the differences were  
 
 statistically significant, the results should be considered with precautions, as the power of performing 
both tests were below the required strength (figure 3.5B).   
The average number of MSP antigens recognized by patients with UM were statistically significantly 
bigger than the number recognized by SM patients, (median, [25%-75% percentile]),  (2, [1 – 3] vs 1, 
[0 – 2], respectively), p<0.001, Mann-Whitney Rank Sum Test (table 3.6.).  
 
 
Table 3.6. The average number of MSP antigens (MSP119, MSP2A and MSP2B) recognized by 
individuals in different study groups: a comparison between all malaria patients and malaria-free 
donors, and between patients with uncomplicated malaria and severe malaria.   
    
Donor group 
 
Number No. of recognized MSP Ags,  
(Median,  25% – 75% percent
P-value 
Malaria patients  
 
223 2, [1  –   2]  
Malaria-Free donors  
 
117 0, [0   –   1]  
 
<0.001 
    
Uncomplicated malar
  
114 2, [1   –   3] 
Severe malaria  
 
109 1, [0   –   2] 
 
<0.001 
 
 
 
3.2.6. The antibody response against MSP antigens: comparison between individual 
complications of severe malaria (SMA, CAM, CM and HTN) 
The prevalence of antibodies against the MSP antigens was markedly different between the individual 
complications of severe malaria. While patients with HTN had MSP antibodies against, at least one of 
the 3 antigens (100%), patients with CAM had MSPall antibody prevalence rate of 43.5%, which was 
significantly lower than that of HTN and CM (83.3%) patients, p=<0.001, Fisher Exact Test, and 
p=0.023, Chi-square, respectively. Patients with SMA had a prevalence rate of Abs against MSPall of 
63.3%, which was significantly lower than that of HTN, p=0.013, Fisher Exact Test. However, patients 
in the different subgroups of  
SM had significantly different ages. The mean age of the subgroups correlated with the prevalence rate 
of MSPall antibodies (figure 3.6.) 
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While the plasma levels of MSP119, MSP2A and MSP2B antibodies were comparable between UM and 
SM patients (0.725 vs 0.76, 0.672 vs 0.549 and 1.128 vs 1.018, respectively).  The number of the MSP 
antigens recognized by patients in the different SM sub-groups was different; patients with HTN 
recognized statistically significant higher number of antigens than patients with CAM and SMA 
(p<0.05, Kruskal-Wallis One Way Analysis of Variance on Rank, Dunn's Method). Although, the age 
difference between the SM subgroups was remarkable, there was no difference in the level of 
antibodies against the three MSP antigens, the mean levels varied between 0.66 and 0.83 (p=0.593). 
Figure 3.6. The MSP Ab response in SM patients, comparison between; convulsion 
associated malaria (CAM), severe malarial anemia (SMA), cerebral malaria (CM) and 
hypotension (HTN). The proportion of patients with Abs against MSP119 , MSP2A or 
MSP2B Ags is indicated by the length of bars. Proportion of patients recognized the 3 
antigens (black), two antigens (light) and one antigen (grey). The age (mean ± SD) of 
the patients in each sub-group is indicated by the line with open circles.  
  
3.2.7. The antibody response against MSP antigens: comparison between fatal and 
non-fatal cerebral malaria 
Seven patients were died due to CM (38.9%, 7/18). The MSP antibody response was comparable 
between fatal and non-fatal CM. The prevalence of MSPall antibodies (100% vs 72.7%), and the 
average number of recognized MSP antigens (1.9 vs 1.3), in fatal and non-fatal CM, respectively, were 
not significantly different. Similarly, were the differences between the levels of antibodies against the 
MSP antigens between the two groups of CM (table 3.7). 
 
 
 
Table 3.7. The cerebral malaria patients, characteristics and anti-MSPs antibody response in patients 
died or survived following the cerebral malaria attack    
   
Ab level Cerebral 
patients 
  
Number Age 
Mean± SD
Anti-MSP
Abs  
No. of Ags
recognize
MSP19 MSPA MSPB 
Died  7 18.7± 
19 
100% 1.9 0.74 0.69 1.19 
 
Survived  
 
11 
 
11.1±  
7.4  
 
72.7% 
 
1.3 
 
0.89
 
0.5 
 
0.77 
 
 No significant differences 
No. = number, Ags = antigens   Ab = antibody 
 3.2.8. Acquisition of anti-MSP antibodies at convalescence (D28) by SM patients. 
The plasma antibodies against MSP antigens were measured in 84 plasma samples obtained from 
patients with SM at convalescence, 28 days after malaria diagnosis, but not all samples were tested for 
antibodies against all MSP antigens. There was no significant change in the prevalence of antibodies 
against MSP antigens 28 days after infection. The prevalence of anti-MSP Abs at D0 to MSP119, 
MSP2A and MSP2B was 45.7%, (32/70), 43.6% (34/78) and 33.3% (25/75), respectively, which was 
almost similar to that at D28, 55.7% (39/70), 50% (39/78) and 33.3% (25/75), respectively. However, 
even if we considered the change of response for the individuals in each group, the changes were not 
significant. For MSP119, 14.3% (10/70) acquired and 4.3% (3/70) lost antibodies against the antigens, 
for MSP2A and MSP2B, 16.7% (13/78), 8% (6/75) acquired and 10.3% (8/78), 8% (6/75) lost antibody 
to the respective antigens. However, upon breakdown of data of SM, the most recognizable finding was 
that, 24.2% (8/33) of patients with SMA, and 00% (0/11) of patients with CM, acquired anti-MSP119 
antibody response at convalescence, but the difference was not significant. In general, the acquisition 
of anti-MSP antibodies at convulscence was neither age nor complication-dependent.  
 
3.3. Antibody response against variant surface antigens (VSA)   
3.3.1. Spectrum and level of antibody reactivity against 
VSA 
The spectrums of antibody reactivity account for how many isolates were recognized 
by the test plasma samples, irrespective of the antibody level. To correlate 
between the 2 indices, we used plasma (n=65) obtained from patients with severe 
malaria at day 0 and the 22 isolates (not all parasites tested with all plasma). 
There was strong correlation between the number of isolates recognized by each 
plasma sample, and the average level of VSA antibody in plasma against each of the 
recognized isolates (CC, 0.727 P < 0.001, Pearson Product Moment Correlation) 
although a number of outliers were recognized (figure 3.7).   
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Thus, when all plasma were considered together and data re-analyzed, the rate of 
recognition  
 
3.3.2. VSA antibody recognition of parasites isolated from 
patient wseverand uncomplicated malaria 
 
 
3.3.2. VSA antibody recognition of parasites isolated from 
patients with severe and uncomplicated malaria 
Parasites and plasma were collected before initiation of the treatment from 
patients with clinically defined malaria syndromes. Plasma also collected from 
asymptomatic malaria free donors and convalescence samples (D28) from some patients 
who have had severe malaria. Plasma also obtained from children with uncomplicated 
malaria living in an area of high malaria transmission in Tanzania (table 3.8).  
 Parasites causing severe malaria have previously been shown to express variable 
surface antigens (VSA) that are more often recognized by plasma IgG than VSA 
expressed by parasites from patients with uncomplicated malaria. Thus, we compared 
the plasma reactivity to parasites isolated from the different patients groups. The 
reactivity to parasites obtained from patients with severe malarial anemia tended 
to be consistently higher than the reactivity to parasites causing cerebral 
malaria, whether or not all panels of plasma were considered together, but the 
Figure 3.7. The correlation between two indices used for evaluation of the 
VSA antibody (Ab) response; the Y axis shows the proportion of isolates 
zed by individual plasma samples (closed circle), and the X axis 
shows the mean level of Abs in these samples. Plasma was obtained from 
patients with severe malaria (n=65) at the time of diagnosis, antibody 
level was scored into 6 levels as explained before.  Generally, plasma with 
broad spectrum of reactivity had on average higher level of antibody 
against individual isolates, with general positive correlation. In the 
insert, the lines represent the mean. 
 differences were not significant (figure 3.8 and figure 3.9B). 
 
 
Table 3.8. The details of the total samples used for the study of the immune response directed against 
variant surface antigens, plasma and parasite donors were mainly classified on clinical bases, date of 
sampling and geographical location   
 
plasma donors 
 
Parasite donors 
MF 
(n=33) 
UM 
(n=64) 
SM-D0 
(n=75) 
SM-D28 
(n=17) 
TZ 
(n=26) 
Total 
(215) 
UM (n= 10 ) 
 
264 568 636 133 260 1861 
CM (n=7 ) 
 
165 364 421 102 182 1234 
SMA (n= 4 ) 
 
132 249 276 55 104 816 
CAM (n=1) 
 
33 62 73 15 26 209 
Total  
(22) 
594 1243 1406 305 572 4120 
Abbreviations: MF= malaria-free donors, UM= uncomplicated malaria, SM= severe, TZ: Tanzanian 
donors. 
 
 
However, when we compared between parasites causing SM and UM there were 
significant differences of parasite causing SMA (50.5%, CI of 47.1 and 53.9 
[412/816]) and CM (48.9%, CI of 46.2 and 51.7 [604/1234]) were significantly higher 
than the rate of recognition of isolates causing UM (42.5, CI of 40.3 and 44.8 
[792/1861]), P < 0.001, Chi-square test (figure 3.9B.)  
There was a considerable difference between the recognition of the individual 
isolates, the best recognized isolate was recognized by 85.6% of the plasma tested 
(119/139). On the other hand only 7% (15/214) of the plasma donors had VSA 
antibodies to the least-recognized parasite. Both of these isolates were obtained 
from patients with UM. 
  
3.3.3. Correlation between parasite donor age and parasite-
VSA recognition rate 
For each parasite the recognition rate counts for how many samples of the tested 
plasma recognized that specific parasite. When we correlated age of parasite donors 
with the frequency of the parasite VSA recognition rate by different panels of 
plasma (antibody), there was an overall trend of an inverse relationship between 
the parasite donor age and parasite recognition rate. But no significant 
correlation was recognized, whether all plasma sets taken together (CC, -0.273, P = 
0.288, Pearson Product Moment Correlation) or each set considered separately. 
However, as seen in figure 3.10, parasites obtained from children (all were aged 
between 1.5 and 11 years), were significantly more recognized than isolates 
obtained from adult (all adults aged between 19 to 27 years), P = 0.021. 
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  Figure 3.8. The prevalence of VSA Abs in different sets of plasma obtained from malaria free donors (MF), patients with; uncomplicated 
malaria (UM), severe malaria at the time of diagnosis (SM-D0), and at 
convalescence (SM-D28) and Tanzanian children with UM  (TZ). The 
isolates were obtained from patients with SMA, CM and UM, The insert 
shows the reactivity to the individual isolates in each group of the 
it
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3.3.4. Plasma reactivity (VSA-Ab spectrum) in malaria 
patient groups and asymptomatic malaria free individuals 
Children (3-5 years of age) living under conditions of high transmission in 
Tanzania had much higher levels and a broader spectrum of anti-VSA antibodies to 
the parasites collected from Sudan than Sudanese children and adults living under 
low and seasonal transmission  (figure 3.11).  
 
Figure 3.9.a. The 
prevalence of VSA 
antibodies in subsets of 
plasma obtained from 
patients with different 
entities of severe 
malaria; severe malaria 
anemia (SMA), malaria 
associated convulsions 
(MAC), and cerebral 
malaria (CM).  
Figure 3.9.b. The 
overall prevalence of 
antibodies against VSA 
antigens expressed by 
isolates obtained from 
patients with different 
clinical presentation of 
P. falciparum malaria; 
SMA, CM and UM. 
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Among the Sudanese donors the VSA-levels were higher in the patients than in the 
asymptomatic malaria-free individuals. There was a tendency that the levels were 
higher in patients with mild disease compared to patients with severe disease, but 
this difference was not statistically significant (figure 3.8).  
Plasma obtained at diagnosis from patients with severe malaria was divided into 
three sub-sets; SMA (n=37), CAM (n=9) and CM (n=17), and data were re-analyzed to 
compare between the three groups. Results showed that plasma from CM patients 
recognized the different isolates in 190 of 370 occasions in which CM plasma mixed 
with parasites (51.4%, 95% confidence interval, CI of 46.3 and 56.4). In SMA 
plasma, the overall parasite  
  
Figure 3.10. The correlation between age of parasite donors 
(children aged 1.5 to 11 years and adults aged 19 to 27 
years) and the proportion of plasma from all panels able to 
recognize the 2 groups of parasites.  Parasites obtained 
from children statistically significantly more recognized 
than isolates obtained from adult. 
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Figure 3.11. The correlation between age of plasma donors and 
prevalence of antibodies against VSA expressed by all 22-parasite 
isolates. The plasma donors were Tanzanian children (A) and all 
other Sudanese plasma donors (B).
 recognition rate was 30.6%, CI95% of 27.2 and 34.1 (212/692), which was 
significantly lower than in CM. (P = 0.001, Chi-square), while CAM plasma had an 
intermediate capacity for parasite recognition of 39.9%, CI of 32.8 and 47 (73/183) 
(figure 3.9A).   
Furthermore, analysis was done for testing the reactivity of the 3 sub-sets of 
plasma from SM patients with the 3 categories of isolates used in the experiments, 
the SMA, CM and UM parasites. Results showed no change in the order of parasite 
recognition seen in figure 3.8 by plasma sub-groups, irrespective of parasite 
source i.e. no unique pattern of reactivity between CM parasite with CM plasma or 
SMA parasite and SMA plasma. 
 
3.3.5. Correlation between plasma donor age and VSA antibody prevalence 
Whether taken together or considered separately as different sets of plasma donors, 
there was no correlation between age and prevalence of VSA antibodies (CC= 0.279 to 
– 0.089 and P=0.51 to 0.76), except for plasma obtained from patients with UM where 
there was an inverse relationship (CC=0.012, P = 0.93, Pearson Product Moment 
Correlation). However, there was a general trend of insignificant decline in 
prevalence of VSA antibody with increasing age for the plasma from Sudanese donors. 
On the other hand there was a positive correlation between age of Tanzanian plasma 
donors and the frequency of parasites VSA recognition, but still not statistically 
significant (CC=0.279, P=0.168) (figure 3.11).    
 
3.3.6. The reactivity of acute (D0) and convalescence (D28) plasma 
against homologous and heterologous parasite isolates 
At the time of diagnosis, 73% (8/11) of the patients with SM and 43% (3/7) of 
patients with UM had detectable VSA antibodies against their own parasites (table 
3.9). Convalescence samples obtained 28 days after initiation of the treatment were 
available from 8 patients with severe disease. In 5 of the patients there was a 
marked increase in the Anti -VSA titer to the homologous parasite and in three an 
overall better recognition of heterologous parasites. 
 
 
 
 
 
Table 3.9. The parasite donor's characterization, levels and spectrum of their plasma antibody 
 reactivity at diagnosis (D0) and convalescence (D28) against variant surface antigens (VSA) of 
parasites isolated from them (homo) and other donors (hetero) respectively.   
Ab response to isolates 
at Day 0 
Ab response to isolates  
at Day 28 
   Plasma  
Donors 
Type of 
 
Donor 
 
Homo isolate 
(Ab level)  
Hetero isolates 
(% responders) Homo isolates
Hetero isolates  
(%) 
MG29 UM 1.5 0 04% (01/22) 
MG16 UM 3.6 0 04% (01/22) 
MG95 UM 5 0 09% (02/22) 
MG35 UM 8 0 68% (15/22) 
MG50 UM 11 2 26% (04/15) 
MG51 UM 6 2 50% (10/20) 
MG31 UM 27 2 68% (15/22) 
Plasma samples were not taken at D
UM patients 
 
 
 
 
 
       
SG60 SMA 1.5 0 10% (02/19) 5 ND 
SG90 SMA 2 1 16% (03/18) 0 26% (04/15) 
SG65 SMA 9 1 31% (06/19) ND ND 
SG112 SMA 22 4 94% (18/19) ND ND 
       
SG45 CM 9 0 63% (14/22) 0 52% (10/18) 
SG93 CM 11 0 00% (00/22) 1 30% (06/20) 
SG21 CM 5 1 68% (15/22) 4 68% (13/19) 
SG9 CM 8 1 81% (18/22) 4 95% (19/20) 
SG35 CM 25 2 23% (05/21) 1 50% (10/20) 
SG43 CM 5 3 63% (14/22) ND ND 
       
SG42 CAM 9 1 50% (11/22) 3 57% (11/19) 
 DISCUSSION 
 
The first objective of this study was to characterize the clinico-epideiological feature of severe malaria 
from a unique setting in an area of markedly unstable transmission. The assessment of the impact of the 
development of immune response against the Plasmodium falciparum  merozoite surface protein and 
variant surface antigens was the second objective of this study. 
The malaria transmission in Gedarif area, as in most of central Sudan (where ∼ 70% of Sudan population 
live), is confined to a short window of two or three months each year, and sometimes is shorter or absent. 
Under such pattern of transmission, a partially protective immunity is acquired and the inhabitants are best 
described as semi-immune population (40,196).  
The overall frequency of severe malaria (SM) among the confirmed cases of malaria was 4.4%, and the 
mortality rate among the severe malaria patients was 6.4%, which accounts for 0.3% of all cases of 
malaria, this finding is coherent with a previously reported rate from other settings (203). Only four types 
of complications were recognized during the study period, the severe malarial anemia (SMA) was the 
commonest (45.4%), followed by convulsions (CAM), cerebral malaria (CM) and hypotension (HTN), 
and 5.4% of the patients had multiple complications. In general, the difference in the rate of severe 
malaria morbidity and mortality between the two seasons was not statistically significant, but the 
frequency of the individual complications changed considerably. While the SMA represented 26.4% of all 
complications in the first season it was increased by 2.4 fold (63.2%) in the second season, the high 
frequency of SMA was not due to multiple visits of individual patients. But, whether or not the unstable 
transmission of malaria accelerates the change of parasite population and consequently the pattern of 
clinical complications is not known and worth prolonged observation. Some complications were not 
recognized during the two malaria seasons e.g. respiratory distress syndrome and renal disorders. These 
complications are commonly recognized in regions like South East Asia (131,204). The absence of the 
respiratory distress syndrome cases among the study population may be due to the fact that most of 
patients with this syndrome die before reaching the hospital.  
Previously, it was reported that uncomplicated malaria in the same area was recognized in all age groups, 
and individuals aged between 5 and 19 years had the highest risk (40). In this study, the highest proportion 
of patients with mild malaria was recognized in the same age group (5 – 19 years), while that for severe 
malaria was in the age group of two to four years. The earlier protection from severe malaria compared 
with uncomplicated malaria is believed to be due to an earlier and faster acquisition of immunity against 
 parasite strains causing non-cerebral severe malaria (205). However, due to the inherent limitations in 
urban hospital-based studies in general (not all malaria patients seen in hospital) it was difficult to 
calculate with accuracy the incidence and the age risk for both mild and severe malaria. 
There is some evidence that malaria infection in the older age groups results in a different form of 
complications as compared to that seen in children, in areas of stable transmission (206). In these areas, 
distinct age-specific patterns of infection and disease are seen (207,208). In this study, we showed that the 
different clinical groups of severe malaria (anemia, convulsions, cerebral malaria, and hypotension) differ 
from each other in critically important clinico-epidemiological indices. We compared five parameters; the 
age, parasite count, hemoglobin level, blood glucose level, and mortality rate, among the groups. Taken 
together, the four clinical entities of severe malaria were found to be strongly statistically significantly 
different from each other in all the five tested parameters (p=0.022 – 0.000, Kruskal-Wallis test). 
However, the comparison between these complications showed that the greatest difference was between 
CM and SMA, and the least difference was between CM and convulsions. The similarity between CM and 
convulsions (except for the age), and the dissimilarity between CM and SMA on clinical and 
epidemiological aspects, looks interesting, and possibly denote resemblance and disparity in pathogenesis 
of these complications, respectively.    
The difference in the age distribution of the different complications in this setting, and between this and 
other settings, was marked and of special importance. It is well known that, there are differences in the 
peak age for CM compared to SMA and also in the distribution of CM and SMA depending on the level of 
Plasmodium falciparum transmission in the area (203,207). The SMA peaks at the age of 6 months to one 
year and CM at the age of two to three years in hyperendemic areas (209-211).  In this study, the mean age 
for SMA was around five years, while that for CM was approximately 14 years. The mean age for both 
complications, was  three times higher in our study area, while the ratio of the peak age for the two 
complications in each site is constant, (a ratio of approximately 1:3). Hypotension was only recognized 
during adulthood with a mean age of 35 years; however, the outcome of treatment was good and fast, with 
the shortest duration of hospital admission. On the contrary, the mean age for malarial convulsions was 
similar to SMA, five years. In general, more than 60% of patients with severe malaria were above five 
years of age, while all patients who died of severe malaria were above this age (with a mean age of 18 
years). 
The lowest parasite count was recognized in patients with SMA, the youngest group of patients, a low 
parasite count was also recognized in individuals with hypotension, the eldest group. The low parasite 
 count in patients with hypotension could be due to the acquired anti-parasitic immunity which increases 
with age (47). However, the role of age-associated acquisition of immunity can not explain the low 
parasite count in patients with SMA.  
Generally, in other studies hypoglycemia is considered as one of the complications of Plasmodium 
falciparum malaria with a prevalence of 10%, it is ascribed to inhibition of gluconeogensis (212), and is 
considered as independent risk of mortality in severe malaria (213).  In this study the blood glucose level 
was highest in patients with CM and lowest in patients with SMA, the difference was significant; also, 
hyperglycemia was very remarkable in the fatal cases of malaria.  
In other studies the glucose production, glucose concentration and gluconeogenesis in UM patients were 
significantly increased, whereas glycogenolysis is decreased and the mechanism by which these changes 
occur is uncertain (214,215). The counterregulatory hormone concentrations were found higher compared 
to healthy control subjects (215,216). In CM patients a doubling in glucose production was reported and 
the authors conclude that CM is characterized by massive stimulation of gluconeogenesis, where the blood 
glucose was found to be 100% derived from gluconeogenesis. The plasma insulin and the hormones that 
antagonize its action were found comparable to those in healthy control except the elevation of plasma 
cortisol (5 times) which is higher than the  
 
elevation observed among UM patients (2 fold) (212). Hyperglycemia also has been reported by Chadee 
and others to be associated with cerebral malaria (217).   
In this study, hyperglycemia in fatal severe malaria was not due to quantitative deficiency of insulin, on 
the contrary insulin levels were extraordinary higher than in nonfatal severe malaria and above the upper 
physiological limits.  Using animal models infected with P. coatneyi, Davis and his coworker (218) 
reported the occurrence of hyperglycemia and insulin resistant in severe malaria and found biochemical 
and histological evidence of severe hepatic pathology. Another study reported reduced tissue insulin 
sensitivity during acute malaria compared with convalescence and also they reported a reduction in liver 
blood flows that associated with hyperlactatemia in fatal malaria cases (219).  
The strong association between hyperglycaemia, hyper-insulinaemia and cerebral malaria fatality, need 
further biochemical explanation. It is of interest to know, how hyperglycemia and hyperinsulinemia 
coexist, and which preceded the other. The other observation is that the youngest patient who died of 
severe malaria had a relatively lower blood glucose level and insulin level, although the sample size is not 
large enough to make such a judgment. 
 In this setting, the CM had an average mortality rate of 39% (45% and 29% in the first and second season, 
respectively), while there was no mortality from other complications. We compared levels of hemoglobin 
and blood glucose between severe fatal and severe non-fatal malaria. To our surprise, patients died of 
severe malaria had higher hemoglobin and glucose levels when compared with patients survived the 
severe attack of malaria. Interestingly, none of the CM patients who also had SMA died (2 patients).  
In order to link the clinical patterns with the immune response to known malaria antigens, the antibodies 
directed toward specific Plasmodium falciparum malaria antigens (Merozoite surface proteins and variant 
surface antigens) were measured. The importance  
of the antibody in the modulation of the disease was reported in previous studies, where; hyperimmune 
sera from African adults were used successfully for management of children or non-immune patients with 
Plasmodium falciparum malaria (99-101). That was an evidence for the importance of antibodies as part 
of the protective, naturally acquired immunity in adults living under intense malaria transmission, since 
the passive transfer of antibodies relief the malaria symptoms. Thousands of parasite antigens were 
identified so far, but antigens eliciting and boosting sufficiently protective immunity were not well-
defined.  
The merozoite surface proteins (MSP) were among the major vaccine candidate proteins (220), and in 
natural infections they were found to modulate infection outcome in uncomplicated malaria 
(158,159,162). However, little is known about the immune response of patients with SM against MSP 
antigens (221). Even more uncommon knowledge is the comparison between the individual complications 
of SM with regard to the MSP response.  
The IgG immune responses against the individual MSP antigens (MSP119, MSP2A and MSP2B), and all 
three Ags taken together (MSPall), were measured. The same data was analyzed from three different 
aspects, to know if any could be related to protection; a. the prevalence of antibodies b. the level of 
antibodies against the recognized antigens c. the number of recognized antigens. Comparisons were made 
between different study groups and sub-groups as explained hereunder. The comparison was made in the 
following order: 1- Between malaria patients and healthy malaria-free donors. 2- Between patients with 
SM and UM. 3- Within the SM group, between patients with SMA, CAM, CM, HTN. 4 - In the CM sub-
group, between fatal CM and non-fatal CM.                   
In this study the prevalence of antibodies against MSP antigens, was significantly associated with partial 
protection from SM. Although, the prevalence of antibodies to MSP2A &B was higher in patients with UM 
compared with SM, the most pronounced effect was that of MSP119 antibodies. Furthermore, the number 
 of the MSP antigens (maximum of three) recognized was also significantly associated with protection 
from SM. However, we found no significant difference in the level (concentration) of anti-MSP antibodies 
between patients with SM and UM.  
The protective effect of anti-MSP antibodies against malaria was thought to be mediated through 
inhibition of erythrocytes invasion by merozoite (150) and that was confirmed in in-vitro studies (222). 
The above-mentioned mechanism implies that, anti-MSP antibodies reduces the parasite multiplication 
(one of the risk factors in SM) rather than prevents the establishment of the infection. That is very much 
coherent with our findings in which the high prevalence of MSP antibodies didn’t prevent the occurrence 
of UM, while the lower prevalence of these antibodies (in the SM group) could be incriminated in the 
progression of the disease to the severe form. A worth noting point about our epidemiological setting is 
that the population is semi-immune to malaria, accordingly, infection mostly presents clinically as 
symptomatic malaria. This study was designed in such a way that it aborts most of the bias possibilities 
referred to by Dodoo and others  (163) regarding the difference in exposure of the study groups, by 
including SM and UM patients in the study. Both groups of patients were similarly exposed and sampled 
at the same time. Thus, our findings regarding the protective effect of anti-MSP antibodies against SM but 
not UM, can explain the contradicting results of other studies, that support (155, 158) or not (163) the 
protective role of MSP antibodies. 
The antibody response to MSP antigens was consistently and significantly age–dependent, half of the 
donors between 1 and 5 years of age were found to have anti-MSP antibodies, and all donors above 45 
years were responders to one or another MSP antigen. The findings of high prevalence and age-
dependence of MSP antibody response were opposite to the findings from West Africa (163), even if we 
correct for age differences of the study populations. The age dependency of the acquisition of anti-MSP is 
in agreement with (158,160,223).     
Further analysis of the SM data, revealed significant differences in prevalence of anti-MSPall antibodies in 
patients with HTN (high) compared with CAM and SMA (low). The prevalence of MSP Abs was higher 
in CM than SMA patients, the difference was not significant, but the prevalence in CAM was significantly 
lower than in CM, although the ages of SMA and CAM were comparable. The differences in MSP 
antibody prevalence between the SM subgroups was largely but not absolutely due to age factor, that 
means there was other complication-specific pattern of response to MSP antigens. The subgroups of this 
same cohort of SM were found to differ significantly in a number of clinico-epidemiological parameter as 
reported above.  
 Around 40% (7/18) of the CM patient died, unexpectedly, the MSP antibody response (prevalence and 
concentration) was generally high in CM, and it was slightly but not significantly higher in fatal CM than 
non-fatal CM. The protective effect of anti-MSP antibodies against malaria was thought to be mediated 
through inhibition of erythrocytes invasion by merozoite as mentioned before (150). If this is true these 
antibodies are not fine specified where the fine specificity (blocking antibodies with overlapping epitopes 
with the inhibitory antibodies that have minor differences in the binding specificity) of natural acquired 
human antibodies were reported to have marked variation between individuals and were found crucial in 
determining their functional efficacy (224). These detected antibodies might not be of the cytophilic 
isotype where the IgG1 and IgG3 were found to predominate in protected subject (225). Or there is a sort 
of polymorphism such as that of FcγRIIa (CD32) among the study population (88)(Cooke et al. 2003). 
This finding may indicate that, the pathogenesis of CM involves factors more important than the 
erythrocytes invasion by merozoite and the parasite multiplication.  
The apparently healthy, MF donors, had significantly low prevalence and concentration of anti-MSP 
antibodies and the number of recognized MSP antigens (MSP119, MSP2A, MSP2B) compared with malaria 
patients. About 19% of the MF donors had PCR-detectable parasitemia. But, there was no difference in 
the MSP antibody response in MF donors with or without PCR-detectable parasitemia. It could be that, in 
asymptomatic donors, submicroscopic parasitemia is not sufficient to elicit MSP antibody response as in 
symptomatic submicroscopic parasitemia (226). The low anti-MSP antibodies response in MF donors was 
an indicator for low exposure to malaria rather than increased susceptibility to SM.  
Considering the different aspects of the antibody responses with respect to clinical outcome of malaria 
infection, it seems that the prevalence of MSP antibodies were more important than the level of MSP 
antibodies, in this setting. However, significantly lower levels of MSP antibodies were recognized in 
apparently healthy MF donors, where it was considered as a sign of exposure. In other studies the 
protective role of anti-MSP antibody response was mainly attributed to the level of antibodies 
(155,160,227,228). 
The most immunogenic of the three MSP antigens, was MSP119, followed by MSP2A and the least 
recognized was MSP2B. This result is in agreement with Riley and her colleagues (158) where the highest 
prevalence of antibodies being detected against regions which are highly conserved between parasites 
isolates. There was a consistency in this pattern of antibody response in all groups and sub-groups of 
plasma analyzed except for the plasma obtained from patients with SMA, in which the most recognized 
antigen was MSP2B. The prevalence of antibodies against MSP antigens in patients with SM was not 
 significantly changed one month after malaria diagnosis. This antibody response inertia over the 
convalescence period in SM patients was in line with previous study carried out in Gabon (221).  
Interestingly, while the prevalence of the MSP antibodies at diagnosis (D0) was strongly age-dependent, 
the acquisition of this Abs over the convalescence period (28 days) was not affected by age or type of SM. 
The explanation for the above findings is that, in SM, either the parasites have fast boosting effect on the 
MSP antibody response, or the patients with SM were more sensitive to MSP antigens. Thus, patients with 
SM have quick response revealed in a form of a high prevalence (63.3 – 100%) of Abs within few days 
after infection (D0), and no significant change thereafter. For further simplification, the high prevalence of 
anti-MSP antibodies at diagnosis (D0) might not be due to a pre-existing antibody, but was likely to be 
due to the fast triggering of response (boosting) following infection. The finding supported that; the MF 
donors had significantly low prevalence of antibodies compared with the malaria patients (at Do), in this 
setting. It is interesting if we can confirm that, the prevalence of anti-MSP Abs was mostly boosting of 
antibody response by current infections, in semi-immune population.                  
 
Plasmodium falciparum erythrocyte surface protein 1 (PfEMP1) is a variant antigen expressed on the 
surface of infected erythrocyte and serve as the parasite- sequestration ligand to endothelial cells. This 
cytoadherence in the deep circulation or the cytoadherence of PRBC with two or more uninfected RBC 
(rosetting) is regarded as an important virulence factor. PfEMP1 antibodies were believed to protect from 
disease by inhibiting sequestration, thus facilitating the destruction of infected erythrocytes in the spleen. 
In addition antibodies disrupting erythrocyte rosettes have been reported to be associated with protection 
from cerebral malaria. 
A total of 4120 parasite/plasma samples were evaluated by flow cytometry to estimate the prevalence and 
level of VSA antibodies against VSA antigens expressed by parasite isolates obtained from patients with 
different clinical grades of malaria. In general, it is believed that the host immune competence with regard 
to VSA antibody response indicates the number of variants recognized and the level of antibody acquired. 
In this line, the plasma that is able to recognize variants expressed by large number of parasites, on 
average contains higher level of antibodies than the plasma that recognized small number of isolates. This 
suggests a link between the two immunological indices; the ability to recognize large number of parasites 
and the ability to mount high level of antibodies against the recognized isolates.   
The overall pattern of interaction between three clinically distinct groups of parasites with the five panels 
of plasma revealed an association between VSA expression/response and malaria infection outcome. 
 However, in figure 3.8, the three lines (parasite groups) did not cross, indicating differences between the 
different clinical entities of malaria with regard to VSA expression/responses. This whole pattern of 
interaction, suggest that neither VSA expression nor VSA Ab response are random events, but are 
relatively structured by the degree of virulence. It was stated before that, following Plasmodium 
falciparum infection (convalescence), there is an induction of VSA Ab response to  
homologous and heterologous isolates (2). In addition to that, we here report that, infections with parasites 
which caused SM induced VSA Ab response to parasites caused the UM. Importantly, the convalescence 
plasma from patients with SM recognized the broadest range of isolates compared to the other panels of 
Sudanese plasma. Another interesting finding was the strikingly high proportion of Tanzanian responders 
(aged 3 – 5 years) to VSA of the Sudanese isolates compared to Sudanese plasma donors (aged 1.5 to 55 
years). Thus, the major determinant of VSA antibody response in this situation was the endemicity of 
malaria in the place of the plasma donor as shown before (229) (hyper-endemic in Tanzania and meso-
endemic in Sudan) rather than the age of the donors.   
The VSA expression of parasite causing SM and UM were different. The best recognized parasites 
isolates were obtained from patients with SMA followed by CM and in all instances they were better 
recognized than UM parasites, and the differences were statistically significant. The trend was maintained 
even when each set of plasma was considered separately, but the differences were below the statistical 
significance. This finding is in line with previous observations (37,230-232). The wide recognition of 
VSA expressed by SMA parasites either indicate; a. a restriction in the number of expressed variants 
(231), b. a dominance of the causative parasite due to chronicity of infection or c. a higher 
immunogenecity of variants expressed by severe malaria parasites, specifically SMA. 
 
An inverse correlation between the ages of the parasite donors and recognition was found i.e. isolates 
obtained from younger patients were better recognized, irrespective of the type of malaria the patient had. 
This general trend was consistent whether the different sets of plasma were analyzed separately or not, but 
in both situations the correlation was not statistically significant. However, when the parasite donors were 
divided into children (1.5 - 11years) and adults (19 - 27 years), isolates obtained from children were 
statistically significantly better recognized. This observation confirms previous reports when only 
uncomplicated malaria samples were used (2), and when both SM and UM samples were used (229,231). 
This consistent finding indicates that, VSA is unique among other malaria antigens, since the cassette of 
variants expressed by the parasite is somehow determined by the host age. That is independent of VSA Ab 
 immune pressure, as the VSA Ab prevalence was not age-dependent in our setting. 
Among the Sudanese donors the VSA-levels were higher in the patients than in the asymptomatic malaria-
free individuals. There was a tendency that the levels were higher in patients with mild disease compared 
to patients with severe disease, but this difference was not statistically significant. This is in agreement 
with the results obtained from Gabon where the VSA antibody level was found significantly lower among 
severe malaria children than their match counterpart mild malaria patients (232). Where this low VSA 
antibody was proposed to be associated with severe malaria and increased susceptibility to malaria attacks.  
An important and unexpected finding was the significantly broader spectrum of reactivity of pre-existing 
VSA Ab in plasma of patients with CM compared with SMA and CAM at the time of diagnosis. However, 
the broadness of plasma reactivity of CM and UM patients were comparable, so, it is more tempting to 
describe SMA patients as having a significantly limited (lower)VSA Ab response.  The younger age of 
SMA patients cannot explain the above observation as we mentioned before. These observations argue the 
immune competence of patients with SMA. This assumption is supported by the failure of patients with 
SMA to clear their chronic parasitemia for months. Equally, it can be said that, patients with CM had a 
normal VSA Ab response at least to the heterogonous parasites i.e. the patients with CM were not 
immunologically jeopardized.    
 
The VSA Ab response was age independent in this setting. Thus there was no positive correlation between 
plasma donor age and prevalence of antibodies, rather in the other panels of plasma there was decline in 
prevalence of antibodies with increasing age. The lack or the slightly inverse correlation between age of 
plasma donor and parasite recognition rate can explain the susceptibility to malaria in all age groups, in 
this setting. An inverse relation between the age of the plasma donors and parasite recognition rate has 
been reported earlier in a study of a cohort of Gabonese children, in an area of low transmission (232). 
However, other studies conducted in malaria hyperendemic areas, proved the opposite (37,231). The age-
independent acquisition of VSA Abs is more indicative for protection than exposure.     
Although our sample size was not large, the presence of low level of VSA Ab against the homologous 
isolates at the time of diagnosis was more common in SM than UM. This is in agreement with the study 
done by Kinyanjui and others (233) where they found small proportion (19%) of patients had antibodies to 
the infecting parasites. On the other hand this result is in contrast to a study of Kenyan children where 
homologous antibodies were absent at the time of diagnosis (58). The reasons for these discrepancies 
could be that in their study the materials were obtained from patients with UM, that they exclusively used 
 children, or the method used was the less sensitive technique, the fluorescent microscopy. The presence of 
homologous antibody at the time of diagnosis might reflect the duration of infection before presentation as 
acquisition of this Abs, as reported before (233) take about two weeks and their decay up to few months 
(234). If that is the case, then SM (including CM) took longer time before presentation than previously 
expected or at least not less than UM do.  
 
4.1 Conclusions 
• Severe malaria (SM) accounts for 4.4% among the confirmed cases of malaria 
•  The mortality rate among the severe malaria patients was 6.4%, which accounts for 0.3% of all 
cases of malaria. 
•  Only four types of severe malaria complications were reported, the severe malaria anemia (SMA) 
was the commonest (45.4%), followed by convulsions (CAM), cerebral malaria (CM) and hypotension 
(HTN), and 5.4% of the patients had multiple complications. 
• A distinct clinical and immuno-epidemiological pattern of severe malaria was found, which is 
markedly different from that described in areas of high malaria transmission.  
• The three merozoite surface proteins (MSP119, MSP2A and MSP2B) studied were 
immunogenic and the prevalence of antibodies against MSP antigens was significantly associated with 
partial protection from SM.  
• The pronounced effect was that of the conserved fragment of MSP1 (MSP119) which is the most 
immunogenic MSP antigens studied. 
•  On the other hand VSA immunogenicity was found to differ from parasite isolate to another.  
• No difference was observed between the acquisition of Ab against conserved and polymorphic MSP 
Ag, where the responsiveness were age dependent. On the other hand the acquisition of Abs against the 
variant antigens (PfEMP1) was age independent. 
• VSA is unique among other malaria Ags, since the cassette of variants expressed by the parasite is 
somehow determined by the host age. 
• There was an association between VSA expression/response and malaria infection 
outcome, suggesting that neither VSA expression nor VSA Ab response are random 
events, but are relatively structured by the degree of virulence.  
• The best recognized parasite isolates were obtained from patients with SMA 
followed by CM and in all instances they were better recognized than UM parasites.  
 • On the other hand, CM plasma had the broadest spectrum of VSA Ab reactivity 
compared with SMA patients who can be described as having a significantly limited 
(lower) VSA Ab response.  
• The patients with CM were not immunologically jeopardized because they had 
normal Ab response compared to UM patients, at least to the heterologous parasites, 
which may indicate the involvement of other factors. 
• MSP (conserved and polymorphic Ags) responses among SM patients were not significantly 
changed one month after malaria diagnosis, whereas convalescent plasma from patients with severe 
malaria developed VSA Ab that recognized the broader range of isolates VSA compared to D0 response. 
 
4.2. Recommendations 
• The strong association between hyperglycaemia, hyper-insulinaemia and cerebral malaria fatality, 
need further biochemical explanation.  
• Study of the antibody subclasses and if possible their fine specificity (minor differences in the 
binding specificity). 
• Study of the different type of polymorphism that might occur in this population and lead to the 
modulation of the immune response such as FcγRII.  
• Finally, the findings of this study in general, suggest that the immunity against severe malaria might 
not be similar to that against uncomplicated malaria, and we support the idea of developing malaria 
vaccines of selective proficiency.   
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 APPENDIX I: Equipment,  material and reagents 
Giemsa stain: 
The Giemsa stock solution was prepared by dissolving 3.8 grams of Giemsa (Avondale Laboratories 
(supplies and services) limited, Banbury, Oxon., England ) powder in 250 ml methanol and 250 ml 
glycerol with vigorous shaking over 3 days. The working solution was prepared by diluting the Giemsa 
stock 1in10 with phosphate buffer pH 7.2 and filtered. 
Parasite freezing Solution: 
180 ml of 4.2 % sorbitol in Normal saline and 70 ml glycerol were mixed and sterile through 0.22 µm 
Millipore filter and stored frozen. 
ELISA equipment material and reagents 
ELISA reader (Labsystems Multiskan MCC/340)  
The antigens 
Recombinant proteins representing:  
1-  The 19 kDa C-terminal fragment of merozoite surface protein (MSP119)  
2-  Group A of MSP2, denoted T9/96 13/14  
3-  Group B of MSP2, FC27 denoted GF/88)  
4   Glutathione-S-transferase (GST) protein  
The conjugate 
Horseradish peroxidase-conjugated to rabbit anti-human IgG, specific for gamma chain (HRP/IgG) 
DAKO A/S, Denmark. 
Coating buffer: 
1.5 grams sodium carbonate (Na2CO3) and 2.93 grams sodium hydrogen carbonate (NaHCO3) were 
dissolved in distilled water and the pH was adjusted to 9.4 - 9.6, the volume completed to one liter with 
distilled water. 
  
Washing buffer: 
 Phosphate buffered saline with 0.05% Tween-20: 
8 grams sodium chloride (NaCl) 
0.2 grams potassium chloride (KCl) 
1.14 grams disodium hydrogen phosphate (Na2HPO4) 
0.2 grams potassium dihydrogen phosphate (KH2PO4) 
Dissolved in distilled water and the pH adjusted to 7.4 and then 0.5 ml of Tween-20 (0.05%) was added 
 and the volume completed to one liter with distilled water. 
 
Substrate buffer: 
Solution A: 0.1 M citric acid solution (9.6 grams of citric acid / 500ml distilled water). 
Solution B: 0.2 M phosphate solution (14.2 gram of disodium hydrogen phosphate / 500 ml distilled 
water). 
The substrate buffer was then prepared by mixing   
6 ml of solution A 
6.4 ml of solution B 
12.5 ml of distilled water 
11 µl of 27.5% hydrogen peroxide (H2O2). From Aldrich 
10 mg O-Phenylenediamine Dihydrochloride tablets. (OPD). From Sigma Chemical Company. 
 
Stop solution: two molar sulphuric acid  (2M H2SO4): 
55.6 ml of concentrated sulphuric acid (BDH) was added carefully to 400 ml of distilled water and finally 
the volume was completed to 500 ml with distilled water. 
 
In vitro parasite culture and FACS (reagents and buffers) 
Thawing solution (sterile 3.5 % NaCl solution in distilled water) 
Washing medium (500 ml RPMI-1640 supplemented with 25 mg Gentamycin (Gibco)) 
Parasite culture medium (500 ml RPMI-1640 (Gibco) supplemented with 25mg Gentamycin (Gibco), 
91.6 mg L-Glutamine (Sigma), 2.5 gram Albumax II (Life Technologies), 10 ml normal human serum and 
10 mg Hypoxanthine (Sigma)) 
a. The AlbumaxII and Hypoxanthine were prepared as mixture where, 100 grams Albumax II and 400 mg 
Hypoxanthine were dissolved in 2 liter of RPMI-1640 and then the solution was filtered through 0.8 mm 
and 0.2 mm filters, then the sterile solution was kept frozen in 50 ml portions till used.   
b. 2.5 ml of Gentamycin stock (10 mg / ml) per 500 ml RPMI-1640 medium. 
 
Uninfected blood 
Uninfected blood type O Rh- or Rh+ collected in sterile filtered Citrate-Phosphate-Dextrose solution 
(CPD) washed 3 times in washing medium and the puffy coat removed the packed cells were suspended in 
washing media and stored in the fridge at 4 OC.  
 
MACS equipment, material and reagents 
 VarioMACS magnet (Miltenyi Biotec) 
Size CS column (Miltenyi Biotec) 
3-way valve for the column 
Top-adapter for column (Miltenyi Biotec) 
Outlet needle for the column (0.9 mm*40 mm 20G needles). The dimensions of the outlet needle regulate 
the flow rate through the column. 
Nippers for securing the needle, for safety the tip of the outlet needle was cut by a pair of nippers before 
passing infected material through the column. 
Phosphate buffered saline with 2% fetal calf serum (PBS2). 
 
FACS equipment, material and reagents 
-2-colour flow cytometer 
Phosphate buffered saline plus 2 % fetal calf serum (PBS2), Plasmodium falciparum late stage infected 
erythrocytes purified by magnetic separation at 2.5 * 106 erythrocytes/ml in PBS2. 
Ethidium bromide (0.1 mg / ml in PBS). 
Human plasma. 
Goat anti-human IgG antibody (DAKO A473). 
Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat IgG antibody (DAKO F250). 
 APPENDIX II 
Severe Malaria Protocol, Clinical questionnaire 
Gedarif teaching hospital & New Helfa Hospital 
 
Sample I D:……….                 Dates: admission: …/…../2000;      discharge …/…../2001 
Name: ……………………………………………………….. …….Gender: M (  ), F (  ) 
Date of birth: …………………….. …………… age: ……………………………………………. 
Residence (detailed): …………………………………………………………….…………….…… 
Contact address:…………………………………………………………………….…………..…… 
Occupation: …………………………………………………………………………………………… 
Tribe: ………………………………………………………………………………………………….. 
For females: pregnant (  ), lactating (  ).                        Last menstrual cycle …………………. 
 
C/O: 
1.History obtained from: patient (  ), relative (  ) 
2.Fever : 
A/ Duration: …………….. Days.                  B/ Grade: mild (  ), moderate (  ), severe (  ) 
C/ continuous (  ), intermittent (  ).           D/ regular (  ) irregular (  ).         E/ rigors (Yes, No ). 
F/ sweating (Yes, No ). 
3.General ill health, headache (  ), joint pain (  ), back pain (  ), fatigue (  ), bitter taste (  ) 
4.Bleeding: no bleeding (  ),   epistaxis (  ),   haematemsis (  ),   haemoptysis (  ),   bleeding 
from other site (……………………………….). 
5.CNS: confusion (  ), convulsions (  ), loss of consciousness (  ), Hallucination (  ), 
Coma (Y, N), duration ………     Seizures : (partial, general), (L side, R side), duration…… 
6.Abdominal symptoms: pain (  ), nausea (  ), anorexia (  ),  vomiting (  ), diarrhoea (  ). 
7.Respiratory symptoms: Cough (  ) , breathlessness (  ). 
8.Urinary system: anuria, polyurea, haematurea 
Medical History: 
1. Malaria history 
• Number of attacks ≥ 1 a year (  ), 1 every two years (  ), 1 ≤ every three years (  ),   not at all 
().  
2. History of severe malaria (Yes, No), what type……………………… 
• Last clinical attack:…………………… Method of diagnosis : laboratory (  ), clinical (  ) 
• Treatment received: ………………………………………………………………… 
3. History of: Diabetes mellitus (  ), hypertension (  ), renal diseases (  ), asthma (  ),              other 
diseases : ………………………………………. 
4. History of prolonged drug use (more than 1 week): ……………………………………… 
Clinical examination: 
General condition:  A/  ill (  ) well (  );    B/  Normal (  ), pale (  ), Jaundiced (  ), cyanosed (  ) 
C/ drowsy (  ), confused (  ), comatose (  ), convulsions (  ), stiff neck (  ). 
Oral Temperature ……..°C           Weight….kg 
Nails:    normal (  ) clubbing (  ),    spooning (  ). 
Blood pressure: ……………, Pulse ……………….., RR ……………… 
Speech: normal (  ), slurred speech (  ), dysphasia (  ). 
Tongue: normal (  ), dry (  ), coated (  ), angular stomatitis (  ). 
Skin: dry (  ), rash (  ). 
 Systemic examination 
1. Central Nervous System: ………………………………………………………………. 
Position: normal (  ), decerebrate (  ), decorticate (  ), opisthotonus (  ). 
……………………………………………………………………… 
2. Respiratory system: rhythm (regular, irregular), hyperventilation (  ), deep slow breathing ( ), 
shallow fast breathing (  ) intercostals recession (  ).           
3. Gastrointestinal system : Liver size, ……cm ,     spleen,………cm 
Others……………………………………………………………………………………… 
4. Genitourinary system: ………………………………………………………………………. 
5. Muscle-skeletal system: …………………………………………………………………….. 
 
Investigations: 
Blood film for malaria: BF…………. 
Species:   falciparum (  ),   vivax (  ),    malariae (  ),     ovale (  ). 
Parasitxe count: ………/µl 
Complete haemogram : 
Hb ……% (……gm/dl),     Haematocrit ………..    Reticulocytes………….TWBC: …………,   
lymphocytes …….%, Neutrohpils ……%, …….Basophils ……%, Esinophils ……% 
Thrombocyte count ………………….                   ESR (1 hour) …….. 
Biochemical analysis: 
Blood glucose: …………………………Urine general: …………………………………. 
- Renal Function Test : 
Blood : pH ……..    Urea . …………., serum creatinine…………plasma bicarbonate. ……… 
 
Widal test for typhoid : ………………………Widal test for brucelosis : ………………………… 
Chest X-ray (when needed) : …………………………………………………………. 
Current treatment 
1- Anti-malarial……………………………………………2.Fluid:……………………………… 
3. Other drugs ……………………………………………4. Blood transfusion:………………. 
Annex (I) For Cerebral malaria (Adults) 
Eye: Ptosis (  ), Nystagmus (  ), squint (  ). 
Pupils: normal (  ), dilated (  ), constricted (  ), fixed (  ). 
Fundi exam: …………………………………………………………………..……………………. 
Cranial nerves: ……………………………………………………………………………………… 
Upper limbs: …………………………………………………………………………………………. 
Lower limbs: …………………………………………………………………………………………. 
Plantar reflex (down going, equivocal, up going) 
Modified Glasgow coma scale (    ) 
a. Best motor response                        b. Verbal response                    c. Eye movement 
5  - Obeys commands (  )                        - Oriented (  )                               - ………………… 
4  - Localized pain (  )                              - Confused (  )                             - Spontaneously (  ) 
 3  - Flexion to pain (  )                              - Inappropriate words (  )             - To speech (  ) 
2  - Extension to pain (  )                          - Incomprehensible sounds (  )    - To pain (  ) 
1  - None (  )                                             - None (  )                                    - Never (  ) 
Annex (II) For Children 
Fontanelle; normal (  ), sunken (  ), bulging (  ), absent (  ). 
Can the child sit without support (Y,N), drink/breastfeed (Y,N). 
Nasal flaring (Y,N) 
Blantyre coma scale 
a. Motor response                               b. Verbal response            c. Eye movement 
2.  - Localized painful stimulus              - Appropriate cry                  - 
1.  - Withdraw limb from pain                - moan / inappropriate cry    - Directed 
0. - Non-specific or absent response    - None                                   - Not directed 
Annex (III) For pregnant ladies 
Gravidity: ……………………………………………………………………………………………... 
Abortions: No…………… causes: fever (  ) others (  ). 
Current pregnancy: …….weeks. 
1st trimester (  ), 2nd trimester (  ), 3rd trimester (  ). 
 
Follow up 
Day 3 ………………………………………………………………………………………………… 
Day 7 ………………………………………………………………………………………………… 
Day 28 ………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
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 اﻟﻤﻮاﻓﻘﺔ ﻋﻦ ﻋﻠﻢ
 
 
 ﺟﺎﻣﻌﺔ اﻟﺨﺮﻃﻮم ﺑﺎﻟﺘﻌﺎون ﻣﻊ ﺑﻌﺾ اﻟﻤﺆﺳﺴﺎت – آﻠﻴﺔ اﻟﻄﺐ –ﻣﺠﻤﻮﻋﺔ أﺑﺤﺎث اﻟﻤﻼرﻳﺎ اﻟﺘﺎﺑﻌﺔ إﻟﻲ ﻣﺮآﺰ أﺑﺤﺎث اﻟﻤﻼرﻳﺎ  -
ﺋﺺ اﻟﻤﻼرﻳѧﺎ اﻟﻤﺰﻣﻨѧﺔ واﻟﻤﻌﻘѧﺪة واﻟﻌﻮاﻣѧﻞ اﻟﺘѧﻲ ﺗѧﺴﺎهﻢ ﻓѧﻲ ﺗﻌﻘﻴѧﺪهﺎ وﻇﻬѧﻮر اﻟﺴﻮداﻧﻴﺔ واﻷورﺑﻴﺔ ﻣﻬﺘﻤѧﺔ ﺑﺪراﺳѧﺔ أﻧﻤѧﺎط وﺧѧﺼﺎ 
  .ﻓﻲ اﻟﺴﻮدان(  اﻟﺦ ... ، اﻷﻧﻴﻤﻴﺎ، اﻟﻤﻼرﻳﺎ اﻟﺪﻣﺎﻏﻴﺔ) اﻟﺤﺎﻻت اﻟﻤﺴﺘﻌﺼﻴﺔ 
ﻟﻘﺪ ﺗﻢ إﺧﺘﻴﺎر ﻣﺴﺘﺸﻔﻲ اﻟﻘﻀﺎرف اﻟﺘﻌﻠﻴﻤﻲ ﻟﻬﺬﻩ اﻟﺪراﺳﺔ ﻧﺴﺒًﺔ ﻟﺘﻔﺸﻲ هﺬا اﻟﻨﻮع ﻣﻦ اﻟﻤﻼرﻳﺎ ﻓѧﻲ اﻟѧﺴﻨﻴﻦ اﻟﻘﻠﻴﻠѧﺔ اﻟѧﺴﺎﺑﻘﺔ  -
ﻄﻘﺔ، وﺳﻴﻜﻮن ﻣﻮﺿﻮع اﻟﺒﺤﺚ هﻮ دراﺳﺔ وﻓﻬﻢ ﻃﺒﻴﻌﺔ اﻟﻤﺮض وهﺬا اﻟﻔﻬﻢ ﻟﺨﺼﺎﺋﺺ اﻟﻤﻼرﻳﺎ اﻟﻤﺰﻣﻨﺔ ﺳﻮف ﻳﺴﺎﻋﺪ ﻓﻲ ﻓﻲ اﻟﻤﻨ 
  .ﺗﻘﻠﻴﻞ ﺣﺎﻻت اﻹﺻﺎﺑﺔ وﺗﺨﻔﻴﻒ ﺣﺪﺗﻬﺎ أو ﻋﻠﻲ أﻗﻞ ﺗﻘﺪﻳﺮ ﻓﻲ ﺳﺮﻋﺔ ﻣﻌﺎﻟﺠﺘﻬﺎ
ﺎﻣѧﻞ وﺗѧﺘﻢ آﻞ اﻟﻤﺮﺿѧﻲ اﻟѧﺬﻳﻦ ﻳѧﺘﻢ إدﺧѧﺎﻟﻬﻢ إﻟѧﻲ اﻟﻤﺴﺘѧﺸﻔﻲ ﺑﻬѧﺬا اﻟﻨѧﻮع ﻣѧﻦ اﻟﻤﻼرﻳѧﺎ ﺳѧﻮف ﻳﺨѧﻀﻌﻮا إﻟѧﻲ آѧﺸﻒ ﻃﺒѧﻲ ﻣﺘﻜ  -
  .ﻣﺘﺎﺑﻌﺘﻬﻢ ﻃﺒﻴًﺎ ﻟﻔﺘﺮة أﻗﻠﻬﺎ أﺳﺒﻮﻋﻴﻦ ﻟﻠﺘﺄآﺪ ﻣﻦ ﺷﻔﺎﺋﻬﻢ اﻟﺘﺎم
 أﻳﺎم وﺑﻌﺪ 7 أﻳﺎم، 3ﻣﻦ اﻟﻤﺮﻳﺾ ﻓﻮر دﺧﻮﻟﻪ اﻟﻤﺴﺘﺸﻔﻲ، ﺛﻢ ﺑﻌﺪ (  ﺳﻲ ﺳﻲ 5)ﺑﻌﺪ اﻟﻔﺤﺺ اﻟﻄﺒﻲ اﻟﺸﺎﻣﻞ ﻳﺘﻢ أﺧﺪ ﻋﻴﻨﺔ دم  -
ﻧѧﺴﺒﺔ )،(margomeaH etelpmoC)ﺷﻬﺮ، هﺬﻩ اﻟﻌﻴﻨﺎت ﺳﻮف ﻳﺘﻢ أﺳﺘﺨﺪاﻣﻬﺎ ﻹﺟﺮاء ﺑﻌﺾ اﻟﻔﺤﻮﺻﺎت ﻣﺜﻞ ﻓﺤﺺ آﺎﻣﻞ ﻟﻠﺪم 
وﻟѧﻦ ﻳﺘﺤﻤѧﻞ اﻟﻤѧﺮﻳﺾ أو ذووﻩ أي (. ﻓﺤѧﺺ ﻋﻤѧﻮﻣﻲ ﻟﻠﺒѧﻮل )ﻟﻠﺘﺄآﺪ ﻣﻦ ﺧﻠﻮ اﻟﺪم ﻣﻦ ﻃﻔﻴѧﻞ اﻟﻤﻼرﻳѧﺎ و ( اﻟﻤﻼرﻳﺎ)، (اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم 
  .أﻋﺒﺎء ﻣﺎدﻳﺔ ﻧﺘﻴﺠﺔ ﻹﺷﺘﺮاآﻪ ﻓﻲ هﺬا اﻟﺒﺤﺚ
  .اﻟﺪراﺳﺔاﻟﺤﻖ ﻓﻲ اﻟﻤﻮاﻓﻘﺔ أو اﻟﺮﻓﺾ ﻓﻲ اﻟﺪﺧﻮل ﻓﻲ هﺬﻩ ( ﺣﺎﻻت اﻹﻏﻤﺎء واﻷﻃﻔﺎل) ﻟﻠﻤﺮﻳﺾ أو ﻣﺮاﻓﻘﻪ  -
  .اﻟﻤﺮﺿﻲ اﻟﺬﻳﻦ ﻻ ﻳﺮﻏﺒﻮن ﻓﻲ اﻟﺪﺧﻮل ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﺳﻮف ﺗﺘﻢ ﻣﺘﺎﺑﻌﺘﻬﻢ ﺑﺎﻟﻄﺮﻳﻘﺔ اﻟﻤﻌﺘﺎدة ﻓﻲ اﻟﻤﺴﺘﺸﻔﻲ -
ﺗﺴﺘﻔﻴﺪ ﻣﻦ إﺷﺘﺮاآﻚ ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﻷﻧﻚ أو ﻗﺮﻳﺒﻚ اﻟﻤﺮﻳﺾ ﺳﻮف ﺗﺘﻢ ﻣﺘﺎﺑﻌﺘﻜﻢ ﻣﺘﺎﺑﻌﺔ ﻟﺼﻴﻘﺔ وﺑﻜﺜﻴٍﺮ ﻣѧﻦ اﻟﻌﻨﺎﻳѧﺔ ﻃѧﻮال  -
  .ﻓﺘﺮة اﻟﺪراﺳﺔ
  . *ﻧﺤﻦ ﻋﻠﻲ أﺗﻢ إﺳﺘﻌﺪاد ﻟﻺﺟﺎﺑﺔ ﻋﻠﻲ أي ﺳﺆال أو إﺳﺘﻔﺴﺎر •
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
